

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:19:44 ON 23 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 21 MAY 2002 HIGHEST RN 420086-04-0
DICTIONARY FILE UPDATES: 21 MAY 2002 HIGHEST RN 420086-04-0

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can tot 143

L43 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2002 ACS

RN 153034-77-6 REGISTRY

CN 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3-[7-Carboxy-9-oxo-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-9H-xanthen-4-yl]propanoic acid

CN LY 292728

FS 3D CONCORD


DR 186912-80-1

MF C34 H29 F O9

CI COM

SR CA

LC STN Files: ADISINSIGHT, CA, CAPLUS, DRUGUPDATES, MEDLINE, TOXCENTER,
USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

18 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

17 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:352783

REFERENCE 2: 134:366682

REFERENCE 3: 134:366681

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

REFERENCE 4: 134:366680
 REFERENCE 5: 134:366679
 REFERENCE 6: 132:246369
 REFERENCE 7: 129:289931
 REFERENCE 8: 129:286007
 REFERENCE 9: 129:255009
 REFERENCE 10: 129:254996

L43 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2002 ACS

RN 153034-73-2 REGISTRY


CN 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-, disodium salt (9CI) (CA INDEX NAME)

MF C34 H29 F O9 . 2 Na

SR CA

LC STN Files: CA, CAPLUS, DRUGUPDATES, TOXCENTER

CRN (153034-77-6)



● 2 Na

6 REFERENCES IN FILE CA (1967 TO DATE)
 6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366682
 REFERENCE 2: 134:366681
 REFERENCE 3: 134:366680
 REFERENCE 4: 134:366679
 REFERENCE 5: 126:74591
 REFERENCE 6: 120:134251

=> d ide can tot 144

L44 ANSWER 1 OF 30 REGISTRY COPYRIGHT 2002 ACS


RN 262429-95-8 REGISTRY

CN Benzenesulfonamide, 4-(dipropylamino)-3,5-dinitro-N-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C13 H17 F3 N4 O8 S2

SR CA
LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

L44 ANSWER 2 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 262429-94-7 REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-7-(2-naphthalenylmethoxy)-8-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H24 O4
SR CA
LC STN Files: CA, CAPLUS

*These are
other impts from
claim 15 (#17 -
could not find)*




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

L44 ANSWER 3 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 262429-93-6 REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-8-propyl-7-(2-quinolinylmethoxy)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H23 N O4
SR CA
LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

L44 ANSWER 4 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 262429-92-5 REGISTRY
CN Benzenesulfonic acid, 3,5-dichloro-2-hydroxy-, 2,4-dichloro-6-
[[[(trifluoromethyl)sulfonyl]amino]sulfonyl]phenyl ester (9CI) (CA INDEX
NAME)
FS 3D CONCORD
MF C13 H6 Cl4 F3 N O8 S3
SR CA
LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369


L44 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 256421-39-3 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, diammonium
salt (9CI) (CA INDEX NAME)
MF C23 H16 O6 . 2 H3 N
SR CA
LC STN Files: CA, CAPLUS
CRN (130-85-8)

●2 NH₃

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:127714


L44 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 235083-90-6 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, strontium salt
 (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . x Sr
 SR CAS Registry Services
 LC STN Files: CHEMLIST
 Other Sources: TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (130-85-8)



●x Sr


L44 ANSWER 7 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 235083-88-2 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, zinc salt
 (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . x Zn
 SR CAS Registry Services
 LC STN Files: CHEMLIST
 Other Sources: TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

CRN (130-85-8)




●x Zn

L44 ANSWER 8 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 220201-66-1 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, aluminum salt
 (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . x Al
 SR CAS Registry Services
 CRN (130-85-8)



●x Al


L44 ANSWER 9 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 207605-38-7 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt,
 hydrate (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . x H2 O . 2 Na
 SR CAS Registry Services
 CRN (130-85-8)



● 2 Na

● x H₂O

L44 ANSWER 10 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 156005-50-4 REGISTRY
 CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H32 O7
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1967 TO DATE)
 4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369


REFERENCE 2: 123:188623

REFERENCE 3: 121:141719

REFERENCE 4: 121:57380

L44 ANSWER 11 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 156005-27-5 REGISTRY
 CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[2-ethyl-5-hydroxy-4-(1H-pyrazol-3-yl)phenoxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD

MF C27 H32 N2 O6
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

REFERENCE 2: 121:57380

L44 ANSWER 12 OF 30 REGISTRY COPYRIGHT 2002 ACS


RN 152608-30-5 REGISTRY

CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)

MF C30 H33 F O6

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1967 TO DATE)
 11 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366684

REFERENCE 2: 134:366682

REFERENCE 3: 134:366681

REFERENCE 4: 134:366680

REFERENCE 5: 134:366679

REFERENCE 6: 132:246369

REFERENCE 7: 129:144547

REFERENCE 8: 126:74591

REFERENCE 9: 125:58323

REFERENCE 10: 124:55467

L44 ANSWER 13 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 147612-00-8 REGISTRY

CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-ethoxy-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN LY 282201

FS 3D CONCORD

MF C26 H34 O7

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:371777

REFERENCE 2: 134:371774

REFERENCE 3: 134:357589

REFERENCE 4: 132:246369

REFERENCE 5: 123:188623

REFERENCE 6: 120:322935

REFERENCE 7: 118:233824

L44 ANSWER 14 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 120072-59-5 REGISTRY

CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN CGS 24115

CN SC 41390

CN SC 41930


FS 3D CONCORD

DR 157062-25-4

MF C28 H36 O7

SR CA

LC STN Files: ADISINSIGHT, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, MEDLINE, PHAR, PROMT, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

55 REFERENCES IN FILE CA (1967 TO DATE)
54 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:161356
REFERENCE 2: 134:371777
REFERENCE 3: 134:371774
REFERENCE 4: 134:366684
REFERENCE 5: 134:357589
REFERENCE 6: 132:246369
REFERENCE 7: 132:203175
REFERENCE 8: 130:217617
REFERENCE 9: 127:239120
REFERENCE 10: 126:166481

L44 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 108652-29-5 REGISTRY
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, antimonate(III),
hexasodium salt (7CI) (CA INDEX NAME)
MF C23 H16 O6 . 2 Na . 2/3 Sb
SR CAOLD
LC STN Files: CAOLD
CRN (130-85-8)




● 2 Na

2/3 Sb(III)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L44 ANSWER 16 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 97582-55-3 REGISTRY
 CN 4H-1-Benzopyran-2-carboxylic acid, 7-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]-4-oxo-8-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C25 H26 O7
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

REFERENCE 2: 103:141966


L44 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 71607-30-2 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt, monohydrate (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . H2 O . 2 Na
 LC STN Files: BEILSTEIN*
 (*File contains numerically searchable property data)
 CRN (130-85-8)



● 2 Na

● H₂O

L44 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 68226-95-9 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, dipotassium salt (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Dipotassium pamoate
 MF C23 H16 O6 . 2 K
 LC STN Files: CA, CAPLUS, CHEMLIST
 Other Sources: EINECS**, NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (130-85-8)




● 2 K

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 107:39830


L44 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 68226-94-8 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, dirubidium
 salt (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . 2 Rb
 LC STN Files: CHEMLIST
 Other Sources: EINECS**, NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (130-85-8)



●2 Rb


L44 ANSWER 20 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 68226-93-7 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, dicesium salt
 (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . 2 Cs
 LC STN Files: CHEMLIST
 Other Sources: EINECS**, NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (130-85-8)



●2 Cs


L44 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 59413-58-0 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, dilithium salt
 (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . 2 Li

CI COM
 LC STN Files: CHEMLIST
 Other Sources: EINECS**, NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (130-85-8)



●2 Li

L44 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 53624-36-5 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, aluminum salt
 (3:1) (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . 1/3 Al
 CI COM
 CRN (130-85-8)




●1/3 Al


L44 ANSWER 23 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 50857-37-9 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, didehydro
 deriv. (9CI) (CA INDEX NAME)
 MF C23 H14 O6
 CI IDS, COM

CM 1

CRN 130-85-8
 CMF C23 H16 O6



L44 ANSWER 24 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 49609-89-4 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, tetrapotassium salt (9CI) (CA INDEX NAME)
 MF C23 H16 O6 . 4 K
 LC STN Files: CA, CAPLUS
 CRN (130-85-8)




● 4 K

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 79:115360

L44 ANSWER 25 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 15537-67-4 REGISTRY
 CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, monosodium salt (8CI) (CA INDEX NAME)
 MF C23 H16 O6 . Na
 CI COM
 LC STN Files: BEILSTEIN*
 (*File contains numerically searchable property data)
 CRN (130-85-8)



● Na

L44 ANSWER 26 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 7681-47-2 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, sodium salt
 (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, sodium salt (8CI)
 OTHER NAMES:
 CN Embonic acid sodium salt
 CN Pamoic acid sodium salt
 CN Sodium embonate
 MF C23 H16 O6 . x Na
 CI COM
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMCATS, CHEMLIST, TOXCENTER,
 USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (130-85-8)



x Na

2 REFERENCES IN FILE CA (1967 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:249165

REFERENCE 2: 76:140335

L44 ANSWER 27 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 7558-68-1 REGISTRY

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, monopotassium salt (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, monopotassium salt (8CI)


OTHER NAMES:

CN Monopotassium pamoate

MF C23 H16 O6 . K

LC STN Files: BIOSIS, CHEMCATS, TOXCENTER

CRN (130-85-8)



● K

L44 ANSWER 28 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 6640-22-8 REGISTRY

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt (6CI, 7CI, 8CI)

OTHER NAMES:

CN Disodium 1,1'-methylenebis(2-hydroxy-3-naphthoate)

CN Disodium pamoate

CN Pamoic acid disodium salt

CN Sodium pamoate

MF C23 H16 O6 . 2 Na

CI COM


LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, IFICDB, IFIPAT, IFIUDB, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

CRN (130-85-8)



● 2 Na

20 REFERENCES IN FILE CA (1967 TO DATE)
 20 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:70079
 REFERENCE 2: 132:339389
 REFERENCE 3: 129:166217
 REFERENCE 4: 120:30562
 REFERENCE 5: 115:231824
 REFERENCE 6: 107:39830
 REFERENCE 7: 103:92844
 REFERENCE 8: 103:42642
 REFERENCE 9: 101:45858
 REFERENCE 10: 100:159366

L44 ANSWER 29 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 145-63-1 REGISTRY

CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino)]bis- (9CI)
 (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[ureylenebis(m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino)]di- (8CI)

OTHER NAMES:

CN 8,8'-[Ureylenebis(m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino)]di-1,3,5-naphthalenetrisulfonic acid

CN Farma

CN Farma 939

CN Fourneau

CN Naganol

CN Naphuride

CN Suramin

CN Suramine

MF C51 H40 N6 O23 S6

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,


BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
 CBNB, CHEMLIST, CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IPA,
 MEDLINE, NAPRALERT, NIOSHTIC, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER,
 TULSA, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)


Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1119 REFERENCES IN FILE CA (1967 TO DATE)
 30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1122 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:322273

REFERENCE 2: 136:321001

REFERENCE 3: 136:319353

REFERENCE 4: 136:307351

REFERENCE 5: 136:304045
 REFERENCE 6: 136:304044
 REFERENCE 7: 136:257216
 REFERENCE 8: 136:244034
 REFERENCE 9: 136:243487
 REFERENCE 10: 136:241690

L44 ANSWER 30 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 130-85-8 REGISTRY

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy- (6CI, 7CI, 8CI)

OTHER NAMES:

CN 2,2'-Dihydroxy-1,1'-dinaphthylmethane-3,3'-dicarboxylic acid

CN 4,4'-Methylenebis[3-hydroxy-2-naphthoic acid]

CN Bis(2-hydroxy-3-carboxy-1-naphthyl)methane

CN Emboic acid

CN Pamoic acid

FS 3D CONCORD

DR 122541-93-9, 67232-45-5, 50857-36-8, 108626-78-4, 47620-91-7

MF C23 H16 O6


CI COM

LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, RTECS*, TOXCENTER, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

105 REFERENCES IN FILE CA (1967 TO DATE)
 13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 106 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:309958

REFERENCE 2: 136:273213
REFERENCE 3: 136:249165
REFERENCE 4: 136:189380
REFERENCE 5: 136:70079
REFERENCE 6: 135:226993
REFERENCE 7: 134:295673
REFERENCE 8: 134:18761
REFERENCE 9: 133:177242
REFERENCE 10: 133:785

=> d ide can

L78 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 9004-10-8 REGISTRY

CN Insulin (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Actrapid

CN Actrapid HM

CN Actrapid MC

CN Decurvon

CN Endopancrine

CN Iletin

CN Insular

CN Insulin Injection

CN Insulyl

CN Iszilin

DR 8049-67-0, 8049-95-4, 9004-12-0, 9045-63-0, 9045-65-2, 9045-66-3,
9045-67-4, 9066-39-1, 9066-40-4, 11081-38-2, 57126-42-8, 37243-75-7,
37294-43-2, 69090-47-7, 88026-11-3, 88026-12-4

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHM,
CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA,
MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PHARMASEARCH, PIRA,
PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VTB

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

72042 REFERENCES IN FILE CA (1967 TO DATE)

1454 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA


72136 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:330564
REFERENCE 2: 136:330558
REFERENCE 3: 136:330513
REFERENCE 4: 136:330415

\Rightarrow

=> d sta que 136

L32 STR



GRAPH ATTRIBUTES:

RSPEC	9	3
-------	---	---

NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

```


L34      39 SEA FILE=REGISTRY SSS FUL L32
L35      15 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 AND 3/NR
L36      8  SEA FILE=REGISTRY ABB=ON  PLU=ON  L35 NOT N/ELS

```

=> d scan 136

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-, (2R)- (9CI)
MF C28 H36 O7

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):30


L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-, (+)- (9CI)
 MF C28 H36 O7

Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 2H-1-Benzopyran-2-carboxylic acid, 7-[[5-(4-acetyl-3-methoxy-2-propylphenoxy)pentyl]oxy]-3,4-dihydro-8-propyl- (9CI)
 MF C30 H40 O7




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(2-ethyl-5-hydroxy-4-methoxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI)
 MF C25 H32 O7




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI)
 MF C28 H36 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[4-acetyl-3-methoxy-2-(2-propenyl)phenoxy]propoxy]-3,4-dihydro-8-propyl- (9CI)
 MF C28 H34 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-, (-)- (9CI)
 MF C28 H36 O7

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-7-[3-[3-methoxy-4-(2-methyl-
 1-oxopropyl)-2-propylphenoxy]propoxy]-8-propyl- (9CI)
 MF C30 H40 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 15:38:20 ON 23 MAY 2002)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 15:38:31 ON 23 MAY 2002

E HELMERHORST E/AU
 L1 17 S E3,E4,E5
 E PLEWRIGHT B/AU
 L2 1 S E4
 L3 17 S L1,L2
 E CURTIN/PA,CS
 L4 3783 S E3-E49
 L5 5 S L3 AND L4
 L6 13 S L3 AND ?INSULIN?
 L7 1 S L6 AND (NONPEPTID? OR NON PEPTID?)
 L8 1 S L7 AND L5,L6
 SEL RN

FILE 'REGISTRY' ENTERED AT 15:41:55 ON 23 MAY 2002

L9 14 S E1-E14
 L10 13 S L9 NOT INSULIN
 L11 4 S L9 AND F/ELS
 L12 1 S L11 AND 5/NR
 L13 12 S L10 NOT L12
 L14 8 S L13 AND OC5-C6/ES
 L15 6 S L14 AND (C25H26O7 OR C28H36O7 OR C27H32N2O6 OR C26H34O7 OR C2
 L16 6 S L13 NOT L15
 L17 12 S L10 NOT L12

FILE 'HCAPLUS' ENTERED AT 15:59:24 ON 23 MAY 2002

L18 16 S L3 NOT L8
 SEL RN

FILE 'REGISTRY' ENTERED AT 15:59:39 ON 23 MAY 2002

L19 13 S E15-E27
 L20 12 S L19 NOT L9
 L21 55552 S 46.150.18/RID AND OC5-C6/ES AND 3/NR
 L22 807 S L21 AND 26/C
 L23 131 S L22 AND 5/O
 L24 59 S L23 AND METHOXY
 L25 46 S L24 NOT N/ELS
 L26 4 S L22 AND C26H34O5
 L27 STR
 L28 0 S L27 CSS
 L29 0 S L27 SAM
 L30 437 S C26H34O5/MF
 L31 6 S L30 AND 46.150.18/RID AND OC5-C6/ES
 L32 STR L27
 L33 1 S L32
 L34 39 S L32 FUL
 SAV L34 HOPE400/A
 L35 15 S L34 AND 3/NR
 L36 8 S L35 NOT N/ELS
 SEL RN L20
 SEL RN L17
 L37 763 S E40-E51/CRN
 L38 63 S L37 NOT (COMPD OR MXS/CI)
 L39 51 S L38 NOT WITH
 L40 19 S L39 AND 4/NR
 L41 18 S L40 NOT UNSPECIFIED
 SEL RN L12
 L42 1 S E52/CRN
 L43 2 S L12,L42
 L44 30 S L17,L41

FILE 'REGISTRY' ENTERED AT 16:19:44 ON 23 MAY 2002

FILE 'HCAOLD' ENTERED AT 16:22:29 ON 23 MAY 2002

L45 0 S L43

FILE 'HCAPLUS' ENTERED AT 16:22:38 ON 23 MAY 2002

L46 21 S L43
 L47 140567 S INSULIN
 L48 334734 S GLUCOSE
 S INSULIN/CN OR GLUCOSE/CN

FILE 'REGISTRY' ENTERED AT 16:23:20 ON 23 MAY 2002

L49 2 S GLUCOSE/CN

FILE 'HCAPLUS' ENTERED AT 16:23:20 ON 23 MAY 2002

L50 121055 S L49

FILE 'REGISTRY' ENTERED AT 16:23:21 ON 23 MAY 2002

L51 1 S INSULIN/CN

FILE 'HCAPLUS' ENTERED AT 16:23:21 ON 23 MAY 2002

L52 71961 S L51
 L53 172109 S L52 OR L50
 L54 21 S L46 OR LY292728 OR LY() (292728 OR 292 728)
 L55 16 S L54 AND (PD<=19990922 OR PRD<=19990922 OR AD<=19990922)
 L56 1 S L54 AND L3,L4
 L57 1 S L54 AND L47,L48,L53
 L58 1 S L54 AND (?INSULIN? OR GLUCOSE OR BLOOD(L)SUGAR OR ?DIABET? OR
 L59 0 S L54 AND (?OBESIT? OR ?OBESE?)
 L60 1 S L56-L58
 E INSULIN/CT
 E E24+ALL

L61 9442 S E11,E10
L62 1 S L54 AND L61
L63 1 S L60,L62
L64 1314 S L44
L65 61 S L64 AND L47,L48,L53,L61
L66 9442 S L61 AND (?INSULIN? OR GLUCOSE OR BLOOD(L) SUGAR OR ?DIABET? OR
L67 458 S L61 AND (?OBESIT? OR ?OBESE?)
L68 8 S L65 AND L66,L67
L69 6995 S L65-L67 NOT INSULIN LIKE GROWTH FACTOR
L70 34 S L69 AND L65
L71 33 S L70 NOT L68
L72 1 S L71 AND ?DIABET?
L73 2 S L63,L72
L74 9 S L51 AND L64
L75 8 S L74 NOT APOPTOSIS/TI
L76 9 S L73,L75
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 16:35:44 ON 23 MAY 2002

L77 14 S E1-E14
L78 1 S L77 NOT L43,L44

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 16:36:35 ON 23 MAY 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 May 2002 VOL 136 ISS 21
FILE LAST UPDATED: 22 May 2002 (20020522/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d l76 all hitstr tot

L76 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:209933 HCAPLUS
DN 132:246369
TI Use of non-peptidyl compounds for the treatment of insulin
-related ailments
IN Helmerhorst, Erik; Plewright, Brian Scott
PA Curtin University of Technology, Australia
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English

Appl.

IC ICM A61K038-28
ICS A61K031-19; A61K031-35
CC 1-10 (Pharmacology)
Section cross-reference(s): 2, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000016798	A1	20000330	WO 1999-AU786	19990917
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9960707	A1	20000410	AU 1999-60707	19990917
	EP 1115422	A1	20010718	EP 1999-947113	19990917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	AU 1998-6091	A	19980922		
	WO 1999-AU786	W	19990917		
OS	MARPAT 132:246369				
AB	The present invention relates to the use of at least a non-peptidyl compd. as a biol. modulator of insulin activity or insulin -related activity for the treatment of insulin -related diseases. Non-peptidyl compds. of the present invention exert their effects by mimicking amino acids spatially located on insulin , enabling those compds. to bind to the insulin receptor or insulin -like receptor causing biol. modulation of the activity of the receptor. A method for identifying a non-peptidyl compd. comprises the steps of: (1) comparing the 3D structure of the non-peptidyl compd. with a 3D pharmacophore of an active site of insulin , and (2) selecting a non-peptidyl compd. The compds. may act either as agonists or antagonists of insulin or insulin -like activity. Pharmaceutical compns. contg. chem. compds. capable of modulating the biol. activity of insulin are also claimed. For example, 4,4'-methylenebis[3- hydroxy-2-naphthalenecarboxylic acid] (IM 025) was an antagonist of insulin action. IM 025 caused a dose-dependent decrease in the incorporation of 32P into FYF peptide in insulin -stimulated tubes and inhibited glucose transport in 3T3L1 cells, with IC50 of 150 and 170 .mu.M, resp. 2,4-Dichloro-6-[N- (trifluoromethanesulfonyl)sulfamoylphenyl-3,5-dichloro-2-hydroxybenzene] sulfonate (IM 103) was an agonist of insulin action displaying a biphasic biol. dose response curve with an apex at concn. of 110 .mu.M and an apparent EC50 of 45 .+- . 7 .mu.M.				
ST	nonpeptidyl insulin receptor agonist antagonist				
	antidiabetic				
IT	Antidiabetic agents				
	Pharmacophores				
	(non-peptidyl compds. modulating insulin activity by mimicking amino acid residues spatially located on insulin and binding to insulin receptors)				
IT	Insulin receptors				
	RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)				
	(non-peptidyl compds. modulating insulin activity by mimicking amino acid residues spatially located on insulin and binding to insulin receptors)				
IT	130-85-8 145-63-1 97582-55-3				
	120072-59-5 147612-00-8 152608-30-5				
	153034-77-6 156005-27-5 156005-50-4				

262429-92-5 262429-93-6 262429-94-7
262429-95-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(non-peptidyl compds. modulating **insulin** activity by mimicking amino acid residues spatially located on **insulin** and binding to **insulin** receptors)

IT 9004-10-8, **Insulin**, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(non-peptidyl compds. modulating **insulin** activity by mimicking amino acid residues spatially located on **insulin** and binding to **insulin** receptors)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Aguilar-Bryan, L; J Biol Chem 1990, P8218 HCAPLUS
- (2) Bahn, H; 1978, P5
- (3) Djuric, S; J Med Chem 1989, V32(6), P1145 HCAPLUS
- (4) Eli Lilly And Company; EP 132366 1985 HCAPLUS
- (5) Eli Lilly And Company; WO 9517183 1995 HCAPLUS
- (6) Harper, R; J Med Chem 1994, V37, P2411 HCAPLUS
- (7) Mount Sinai School Of Medicine; AU 9055415 1990 HCAPLUS
- (8) Novo Nordisk AS; AU 8654495 1986 HCAPLUS
- (9) Novo Nordisk AS; AU 8662066 1987 HCAPLUS
- (10) Novo Nordisk AS; AU 8813976 1988 HCAPLUS
- (11) Novo Nordisk AS; AU 8822636 1990 HCAPLUS
- (12) Novo Nordisk AS; AU 9048344 1990 HCAPLUS
- (13) Sawyer, J; J Med Chem 1993, V36, P3982 HCAPLUS


IT 130-85-8 145-63-1 97582-55-3
120072-59-5 147612-00-8 152608-30-5
153034-77-6 156005-27-5 156005-50-4
262429-92-5 262429-93-6 262429-94-7
262429-95-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(non-peptidyl compds. modulating **insulin** activity by mimicking amino acid residues spatially located on **insulin** and binding to **insulin** receptors)

RN 130-85-8 HCAPLUS


CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA INDEX NAME)




RN 145-63-1 HCAPLUS

CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino)]bis- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




RN 97582-55-3 HCAPLUS
 CN 4H-1-Benzopyran-2-carboxylic acid, 7-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]-4-oxo-8-propyl- (9CI) (CA INDEX NAME)




RN 120072-59-5 HCAPLUS
 CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)




RN 147612-00-8 HCAPLUS
 CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-ethoxy-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)




RN 152608-30-5 HCAPLUS
 CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)




RN 153034-77-6 HCAPLUS
 CN 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo- (9CI) (CA INDEX NAME)




RN 156005-27-5 HCAPLUS
 CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[2-ethyl-5-hydroxy-4-(1H-pyrazol-3-yl)phenoxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)




RN 156005-50-4 HCAPLUS
 CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)




RN 262429-92-5 HCAPLUS
 CN Benzenesulfonic acid, 3,5-dichloro-2-hydroxy-, 2,4-dichloro-6-[[[(trifluoromethyl)sulfonyl]amino]sulfonyl]phenyl ester (9CI) (CA INDEX NAME)




RN 262429-93-6 HCAPLUS
 CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-8-propyl-7-(2-quinolinylmethoxy)- (9CI) (CA INDEX NAME)



RN 262429-94-7 HCAPLUS
 CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-7-(2-naphthalenylmethoxy)-8-propyl- (9CI) (CA INDEX NAME)



RN 262429-95-8 HCAPLUS
 CN Benzenesulfonamide, 4-(dipropylamino)-3,5-dinitro-N-
 [(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)



IT 9004-10-8, Insulin, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (non-peptidyl compds. modulating insulin activity by
 mimicking amino acid residues spatially located on insulin
 and binding to insulin receptors)
 RN 9004-10-8 HCAPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:208513 HCAPLUS

DN 131:53970

TI Antioxidants improve impaired insulin-mediated glucose uptake and prevent
 migration and proliferation of cultured rabbit coronary smooth muscle
 cells induced by high glucose

AU Yasunari, Kenichi; Kohno, Masakazu; Kano, Hiroaki; Yokokawa, Koji; Minami,
 Mieko; Yoshikawa, Junichi

CS First Department of Internal Medicine, Osaka City University Medical
 School, Osaka, 545-8586, Japan

SO Circulation (1999), 99(10), 1370-1378

CODEN: CIRCAZ; ISSN: 0009-7322

PB Lippincott Williams & Wilkins

DT Journal

LA English

CC 1-12 (Pharmacology)

Section cross-reference(s): 14

AB To explore the role of intracellular oxidative stress in high
 glucose-induced atherogenesis, we examd. the effect of probucol and/or
 .alpha.-tocopherol on the migration and growth characteristics of cultured
 rabbit coronary vascular smooth muscle cells (VSMCs). Chronic
 high-glucose-medium (22.2 mmol/L) treatment increased platelet-derived
 growth factor (PDGF)-BB-mediated VSMC migration, [3H]thymidine
 incorporation, and cell no. compared with VSMCs treated with
 normal-glucose medium (5.6 mmol/L+16.6 mmol/L mannose). Probucol and
 .alpha.-tocopherol significantly suppressed high glucose-induced increase
 in VSMC migration, cell no., and [3H]thymidine incorporation. Probucol
 and .alpha.-tocopherol suppressed high glucose-induced elevation of the

cytosolic ratio of NADH/NAD⁺, phospholipase D, and membrane-bound protein kinase C activation. Probucol, .alpha.-tocopherol, and calphostin C improved the high glucose-induced suppression of insulin-mediated [3H]deoxyglucose uptake. Chronic high-glucose treatment increased the oxidative stress, which was significantly suppressed by probucol, .alpha.-tocopherol, suramin, and calphostin C. These findings suggest that probucol and .alpha.-tocopherol may suppress high glucose-induced VSMC migration and proliferation via suppression of increases in the cytosolic ratio of free NADH/NAD⁺, phospholipase D, and protein kinase C activation induced by high glucose, which result in redn. in intracellular oxidative stress.

- ST glucose coronary atherogenesis antioxidant probucol tocopherol
 IT Platelet-derived growth factors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (BB; antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)
- IT Atherosclerosis
 Oxidative stress, biological
 (antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)
- IT Artery
 (coronary; antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)
- IT Antioxidants
 (pharmaceutical; antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)
- IT Blood vessel
 (smooth muscle; antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)
- IT 50-99-7, D-Glucose, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)
- IT 145-63-1, Suramin 9004-10-8, Insulin, biological studies
 121263-19-2, Calphostin C
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)
- IT 59-02-9, .alpha.-Tocopherol 23288-49-5, Probucol
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)
- IT 9001-87-0, Phospholipase D 141436-78-4, Protein kinase C
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)


RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

- RE
 (1) Bass, D; J Immunol 1983, V130, P1910 HCAPLUS
 (2) Baynes, J; Diabetes 1991, V40, P405 HCAPLUS


- (3) Bornfeldt, K; J Clin Invest 1994, V93, P1266 HCAPLUS
- (4) Despres, J; N Engl J Med 1996, V334, P952 HCAPLUS
- (5) Farese, R; J Biol Chem 1993, V268, P19949 HCAPLUS
- (6) Hansen, P; Am J Physiol 1997, V273, PE28 HCAPLUS
- (7) Hansen, P; Endocrinol Metab V36
- (8) Kelllerer, M; Diabetes 1994, V43, P447 HCAPLUS
- (9) King, G; J Clin Invest 1983, V71, P974 HCAPLUS
- (10) Kunisaki, M; Diabetes 1994, V43, P1372 HCAPLUS
- (11) Lassegue, B; Biochem J 1993, V292, P509 HCAPLUS
- (12) Machlin, L; FASEB J 1987, V1, P441 HCAPLUS
- (13) Ohara, Y; Arterioscler Thromb Vasc Biol 1994, V14, P1007 HCAPLUS
- (14) Parthasarathy, S; J Clin Invest 1986, V77, P641 HCAPLUS
- (15) Parthasarathy, S; J Clin Invest 1992, V89, P1618 HCAPLUS
- (16) Rao, G; Circ Res 1992, V70, P593 HCAPLUS
- (17) Ross, R; N Engl J Med 1986, V314, P488 MEDLINE
- (18) Saltiel, A; Diabetes 1996, V45, P1661 HCAPLUS
- (19) Stein, B; Circulation 1995, V91, P979 MEDLINE
- (20) Suudaresan, M; Science 1995, V270, P296
- (21) Vinson, J; Diabetes 1989, V38, P1036 HCAPLUS
- (22) Wallenstein, S; Circ Res 1980, V47, P1 MEDLINE
- (23) Williams, B; Diabetes 1992, V41, P1464 HCAPLUS
- (24) Williamson, J; Diabetes 1993, V42, P801 HCAPLUS
- (25) Yasunari, K; Arterioscler Thromb Vasc Biol 1995, V15, P2207 HCAPLUS
- (26) Yasunari, K; Circ Res 1997, V81, P953 HCAPLUS
- (27) Yasunari, K; Hypertension 1996, V28, P159 HCAPLUS

IT 145-63-1, Suramin 9004-10-8, Insulin, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)
 RN 145-63-1 HCAPLUS
 CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 9004-10-8 HCAPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 AN 1995:546945 HCAPLUS
 DN 122:282211
 TI Method of detecting cytopenia that is mediated by drug-dependent antibody binding to blood cells
 IN Aster, Richard H.; Curtis, Brian R.
 PA Blood Center of Southeastern Wisconsin, Inc., USA
 SO PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM G01N033-53
 ICS G01N033-554; G01N033-555
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 9, 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9508116	A1	19950323	WO 1994-US10333	19940915
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5585243	A	19961217	US 1993-120837	19930915
	AU 9476208	A1	19950403	AU 1994-76208	19940915
PRAI	US 1993-120837		19930915		
	WO 1994-US10333		19940915		
AB	Drug-dependent antibodies that bind to granulocytes, erythrocytes, platelets or membrane proteins derived from these cells, in the presence of a drug, but not in its absence, can be detected using a sensitive assay. Detection of the drug-dependent antibodies permits diagnosis of cytopenia mediated by the drug. The method is applicable to a wide variety of drugs. Flow cytom. histograms for e.g. detection of probenecid-dependent antibodies that bind red blood cells are included, and mean 142platelet immunofluorescence values obtained in studies with drug-induced antibodies are tabulated.				
ST	drug cytopenia diagnosis antibody blood cell; immunoassay drug mediated cytopenia diagnosis; antibody drug dependent cytopenia diagnosis				
IT	Agranulocytosis Blood analysis Blood platelet Erythrocyte				

Pharmaceuticals

Urine analysis

(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Interferons

Sulfonamides

Urethane polymers, biological studies

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BIOL (Biological study); PROC (Process)

(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Complement

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)

(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Albumins, analysis

RL: ARU (Analytical role, unclassified); ANST (Analytical study)

(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Antibodies

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Pharmaceutical natural products

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BIOL (Biological study); PROC (Process)

(digitalis, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Blood corpuscle

(disease, cytopenia, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Blood platelet

(disease, thrombocytopenia, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Cytometry

(flow, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Leukocyte

(granulocyte, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Anemia (disease)

(hemolytic, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Proteins, specific or class

RL: ARU (Analytical role, unclassified); ANST (Analytical study)

(membrane-assocd., detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Sulfonamides

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BIOL (Biological study); PROC (Process)

(sulfonyleureas, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT

50-12-4, Mesantoin 50-18-0, Cyclophosphamide 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 51-06-9, Procainamide 51-21-8, 5-Fluorouracil 51-52-5, Propylthiouracil 52-01-7, Spironolactone 52-67-5, Penicillamine 52-86-8, Haloperidol 53-86-1, Indomethacin 54-05-7, Chloroquine 54-21-7, Sodium salicylate 54-31-9, Furosemide 54-85-3, Isoniazid 55-63-0, Nitroglycerin 56-53-1, Diethylstilbestrol 56-54-2, Quinidine 56-75-7, Chloramphenicol 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-53-4, Meprobamate 57-66-9, Probenecid 57-67-0, Sulfaguanidine 57-92-1, Streptomycin, biological studies 58-14-0, Primethamine 58-15-1, Aminopyrine 58-25-3,

Chlordiazepoxide 58-38-8, Prochlorperazine 58-54-8, Ethacrynic acid 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 58-94-6D, Thiazide, derivs. 59-66-5, Acetazolamide 59-92-7, L-Dopa, biological studies 60-54-8, Tetracycline 60-56-0, Methimazole 60-80-0, Antipyrine 60-99-1, Methotrimeprazine 61-32-5, Methicillin 61-72-3, Cloxacillin 62-44-2, Phenacetin 63-74-1, Sulfanilamide 64-77-7, Tolbutamide 65-49-6, p-Aminosalicylic acid 67-20-9, Nitrofurantoin 68-89-3, Metamizole 69-23-8, Fluphenazine 69-53-4, Ampicillin 70-51-9, Desferrioxamine 71-63-6, Digitoxin 72-14-0, Sulfathiazole 74-55-5, Ethambutol 76-75-5, Thiopental 77-02-1 77-36-1, Chlorthalidone 77-65-6, Carbromal 79-57-2, Oxytetracycline 80-08-0 80-35-3, Sulfamethoxypyridazine 81-81-2, Warfarin 85-73-4, Phthalylsulfathiazole 86-54-4, Hydralazine 91-75-8, Antazoline 92-84-2D, Phenothiazine, derivs. 94-20-2, Chlorpropamide 96-83-3, Iopanoic acid 97-77-8, Disulfiram 99-66-1, Valproic acid 100-33-4, Pentamidine 103-90-2, Acetaminophen 110-85-0, Piperazine, biological studies 113-45-1, Methylphenidate 113-92-8 114-07-8, Erythromycin 115-67-3, Paramethadione 116-43-8 117-96-4, Diatrizoate 118-42-3, Hydroxychloroquine 122-11-2, Sulfadimethoxine 125-33-7, Primidone 125-40-6, Butabarbital 125-84-8, Aminogluthethimide 127-56-0 127-69-5, Sulfisoxazole 127-79-7, Sulfamerazine 129-20-4, Oxyphenbutazone 130-95-0, Quinine 135-07-9 137-58-6, Lidocaine 141-90-2, Thiouracil 144-82-1, Sulfamethizole 145-63-1, Suramin 148-24-3, 8-Quinololinol, biological studies 148-82-3, Melphalan 153-61-7, Cephalothin 154-21-2, Lincomycin 154-42-7, Thioguanine 298-46-4, Carbamazepine 303-81-1, Novobiocin 315-30-0, Allopurinol 339-44-6, Glymidine 359-83-1, Pentazocine 364-98-7, Diazoxide 389-08-2, Nalidixic acid 396-01-0, Triamterene 439-14-5 474-25-9, Chenodeoxycholic acid 519-98-2, Noraminopyrine 525-66-6, Propranolol 528-92-7, Allylisopropylacetylurea 554-57-4, Methazolamide 555-30-6, .alpha.-Methyldopa 561-27-3, Heroin 599-79-1, Sulfasalazine 636-54-4, Clopamide 644-62-2 709-98-8, Propanil 723-46-6 738-70-5, Trimethoprim 1397-89-3, Amphotericin B 1402-38-6, Actinomycin 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1622-61-3, Clonazepam 1668-19-5, Doxepin 1951-25-3, Amiodarone 2033-94-5, Centalun 3737-09-5, Disopyramide 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5534-95-2, Pentagastrin 5786-21-0, Clozapine 6452-71-7, Oxprenolol 6990-06-3, Fusidic acid 7439-93-2D, Lithium, salts 8025-81-8, Spiramycin 8064-90-2 9004-10-8, Insulin, biological studies 10238-21-8, Glibenclamide 11056-06-7, Bleomycin 11111-12-9, Cephalosporin 13292-46-1, Rifampicin 14028-44-5, Amoxapine 14769-73-4, Levamisole 15307-86-5, Diclofenac 15686-71-2, Cephalixin 15687-27-1, Ibuprofen 16034-77-8, Iocetamic acid 17230-88-5, Danazol 18323-44-9, Clindamycin 18378-89-7, Plicamycin 20830-75-5, Digoxin 21829-25-4, Nifedipine 22204-53-1, Naproxen 22232-54-8, Carbimazole 24219-97-4, Mianserin 24526-64-5, Nomifensine 25803-14-9, Clometacine 26171-23-3, Tolmetin 31828-71-4, Mexiletine 31879-05-7, Fenoprofen 32986-56-4, Tobramycin 34444-01-4, Cephmandole 36322-90-4, Piroxicam 37300-21-3 38194-50-2, Sulindac 38304-91-5, Minoxidil 40180-04-9, Tienilic acid 41708-72-9, Tocainide 42399-41-7, Diltiazem 51234-28-7, Benoxaprofen 51481-61-9, Cimetidine 51481-65-3, Mezlocillin 51803-78-2, Nimesulide 54350-48-0, Etretinate 55142-85-3, Ticlopidine 59865-13-3, Cyclosporine A 60719-84-8, Amrinone 61477-96-1, Piperacillin 62054-23-3, Phthalazinol 62571-86-2, Captopril 63469-19-2, Apalcillin 64872-76-0, Butoconazole 64952-97-2, Moxalactam 66357-35-5, Ranitidine 69655-05-6, Didanosine 69712-56-7, Cefotetan 70052-12-9 70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 73384-59-5 76824-35-6, Famotidine 79517-01-4, Octreotide acetate 79902-63-9, Simvastatin 81103-11-9, Clarithromycin 86386-73-4, Fluconazole 87626-55-9, Flavone-8-acetic acid 99614-02-5, Ondansetron 100817-46-7, Stibogluconic acid
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)


(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT 67-68-5, analysis
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (detection of cytopenia mediated by drug-dependent antibody binding to blood cells)


IT 145-63-1, Suramin 9004-10-8, Insulin, biological studies
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BIOL (Biological study); PROC (Process)
 (detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

RN 145-63-1 HCAPLUS
 CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 9004-10-8 HCAPLUS
 CN Insulin (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 AN 1994:430214 HCAPLUS


DN 121:30214
TI Mass spectrometric molecular-weight determination of highly acidic compounds of biological significance via their complexes with basic polypeptides
AU Juhasz, Peter; Biemann, Klaus
CS Dep. Chem., Massachusetts Institute of Technol., Cambridge, MA, 02139-4307, USA
SO Proc. Natl. Acad. Sci. U. S. A. (1994), 91(10), 4333-7
CODEN: PNASA6; ISSN: 0027-8424
DT Journal
LA English
CC 9-5 (Biochemical Methods)
Section cross-reference(s): 73
AB Highly acidic compds. that are difficult to ionize by matrix-assisted laser desorption ionization give excellent spectra when mixed with a basic peptide or protein to form a noncovalent complex. This phenomenon makes it possible to det. the mol. wts. of polysulfated, polysulfonated, and polyphosphorylated biomols. such as cysteic acid-contg. peptides, oligonucleotides, heparin-derived oligosaccharides, and suramin (a drug contg. 2 trisulfonated naphthalene moieties). Peptides and small proteins rich in arginine were used as the basic components. The extent of complex formation correlates with the no. of phosphate and sulfate groups in the acidic component and with the no. of arginines in the basic component. Neither the acidic amino acid residue aspartic and glutamic acid nor the basic lysine and histidine contribute to complex formation. For oligonucleotides, histone H4 was found to be the best complexing agent investigated. The anal. utility of the complex formation is demonstrated by the mol.-mass detn. of acidic compds. from 500 to 6000 Da at the picomole or sub-picomole level with an accuracy of $\pm 0.1\%$ or better and by the absence of alkali cation adducts.
ST acidic biochem mol wt detn; mass spectrometry acidic compd mol wt; basic polypeptide complex acidic compd mass
IT Mass spectrometry
(MALDI (matrix-assisted laser desorption ionization), mol. wt. of highly acidic biol. compds. detn. with basic polypeptides for complex formation and)
IT Molecular weight
(detn. of, of highly acidic biol. compds., with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
IT Oligosaccharides
RL: ANST (Analytical study)
(heparin-derived, mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
IT Histones
RL: ANST (Analytical study)
(H4, calf thymus, mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)
IT Peptides, uses
Proteins, specific or class
RL: USES (Uses)
(arginine-contg., mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)
IT Molecules
(biochem., highly acidic, mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
IT Nucleotides, properties
RL: PRP (Properties)
(oligo-, mol. wt. of, detn. of, with basic polypeptides for complex

- formation and matrix-assisted laser desorption ionization mass spectrometry)
- IT Nucleotides, properties
RL: PRP (Properties)
(oligo-, deoxyribo-, mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
- IT 54-20-6, 5-(Trifluoromethyl)uracil 110-15-6, Butanedioic acid, uses 118-92-3, Anthranilic acid 331-39-5, Caffeic acid 530-59-6, Sinapinic acid 28166-41-8, .alpha.-Cyano-4-hydroxycinnamic acid
RL: ANST (Analytical study)
(as matrix in MALDI mass spectrometric mol. wt. detn. of highly acidic biol. compds. via their complexes with basic polypeptides)
- IT 60267-61-0, Ubiquitin
RL: ANST (Analytical study)
(bovine, mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)
- IT 9007-43-6, Cytochrome c, uses
RL: USES (Uses)
(horse, mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)
- IT 20449-79-0P, Melittin 60482-95-3P, Neurotensin(8-13) 61214-51-5P
77259-54-2P, Dynorphin(1-9) 81493-98-3P 88894-91-1P 123251-89-8P
155964-83-3P 155964-84-4P 155964-85-5P
RL: PREP (Preparation)
(mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)
- IT 145-63-1, Suramin 110577-00-9
RL: PRP (Properties)
(mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
- IT 55508-38-8
RL: PRP (Properties)
(mol. wt. of, detn. of, with calf thymus histone H4 for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
- IT 9005-49-6, Heparin, biological studies
RL: BIOL (Biological study)
(oligosaccharides derived from, mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
- IT 9004-10-8, Insulin, analysis
RL: ANST (Analytical study)
(oxidized A chain of bovine, MALDI mass spectra of mixt. of bovine ubiquitin and)
- IT 145-63-1, Suramin
RL: PRP (Properties)
(mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
- RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino)]bis- (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B




IT 9004-10-8, Insulin, analysis
 RL: ANST (Analytical study)
 (oxidized A chain of bovine, MALDI mass spectra of mixt. of bovine
 ubiquitin and)
 RN 9004-10-8 HCAPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 AN 1993:6982 HCAPLUS
 DN 118:6982
 TI Preparation of [(heterocyclyl)(alkyl)]phenyl amidines and guanidines as
 hypoglycemics.
 IN Gopalan, Balasubramanian
 PA Boots Co., PLC, UK
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 123 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 IC ICM C07D211-56
 ICS C07D207-14; C07D233-02; C07D239-04; C07D265-30; C07D223-12
 CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))

FAN.CNT 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
-----		---	-----	-----	-----
PI	CN 1057648	A	19920108	CN 1990-103295	19900629
	CN 1037346	B	19980211		
OS	CASREACT 118:6982; MARPAT 118:6982				
GI					



AB The title compds. [I; R1, R2 = (methoxy) aliph. hydrocarbyl, cycloalkyl; or NR1R2 = N-contg. heterocyclyl; R3 = alkyl, cycloalkyl, (substituted) amino; R5 = (methoxy) aliph. hydrocarbyl; R6 = H, (substituted) alkyl, cycloalkyl; R7 = H, alkyl, halo, methoxy, CO2Me, SO2Me; R3R5 may form part of a ring; with provisos] are prepd. E.g., 1-benzyl-3-methyl-2-pyrrolidinone in benzene contg. POCl3 was heated with 4-(2-aminophenyl)morpholine at 70.degree. for 24 h to give 4-[2-(1-benzyl-3-methyl-2-pyrrolidinylideneamino)phenyl]morpholine. This decreased the blood sugar level by .gtoreq.25% in rats 2 or 4 h after they were injected s.c. with **glucose**. Pharmaceuticals contg. I were formulated.

ST amidine heterocyclylalkylphenyl prepn hypoglycemic; guanidine heterocyclylalkylphenyl prepn hypoglycemic; heterocyclylalkylphenyl amidine guanidine; hypoglycemic amidine guanidine

IT **Antidiabetics** and Hypoglycemics
((heterocyclyl)(alkyl)]phenyl amidines and guanidines)

IT Amidines
RL: SPN (Synthetic preparation); PREP (Preparation)
(aryl, prepn. of, as hypoglycemics)

IT 131679-02-2, N-(2-Morpholinomethylphenyl)morpholine-4-formamidine difumarate
RL: RCT (Reactant)
(234prepn. of, as hypoglycemic)

IT 131675-72-4P, 4-[2-(2-Piperidinylideneamino)phenyl]morpholine
131675-74-6P, 4-[2-(1-Methyl-2-piperidinylideneamino)phenyl]morpholine
131675-75-7P 131675-76-8P 131675-77-9P 131675-78-0P 131675-80-4P
131675-81-5P 131675-82-6P 131675-83-7P, 4-[2-(1,3,3-Trimethyl-2-pyrrolidinylideneamino)phenyl]morpholine 131675-84-8P 131675-86-0P
131675-87-1P 131675-88-2P 131675-90-6P 131675-91-7P 131675-93-9P
131675-94-0P 131675-95-1P 131675-96-2P 131675-97-3P 131675-98-4P
131675-99-5P 131676-01-2P 131676-02-3P, 4-[4-Chloro-2-(2-piperidinylideneamino)phenyl]morpholine 131676-03-4P 131676-04-5P
131676-05-6P 131676-06-7P 131676-07-8P 131676-08-9P 131676-09-0P
131676-10-3P 131676-13-6P 131676-14-7P, 4-[2-(3-Methyl-2-pyrrolidinylideneamino)phenyl]morpholine fumarate 131676-15-8P
131676-16-9P 131676-17-0P, 1-Butyl-2-(2-morpholinophenyl)-3-acetamidine
131676-19-2P 131676-21-6P 131676-23-8P 131676-25-0P 131676-26-1P
131676-27-2P 131676-28-3P 131676-29-4P 131676-30-7P 131676-31-8P
131676-32-9P 131676-33-0P 131676-34-1P 131676-35-2P 131676-36-3P
131676-37-4P 131676-38-5P 131676-39-6P 131676-40-9P 131676-41-0P
131676-42-1P 131676-43-2P 131676-44-3P 131676-45-4P 131676-46-5P
131676-47-6P 131676-48-7P 131676-49-8P 131676-50-1P 131676-51-2P
131676-52-3P 131676-53-4P 131676-54-5P 131676-55-6P 131676-56-7P

131676-57-8P 131676-59-0P 131676-60-3P 131676-62-5P 131676-63-6P
131676-64-7P 131676-65-8P 131676-66-9P 131676-67-0P 131676-69-2P
131676-70-5P 131676-71-6P 131676-72-7P 131676-73-8P 131676-74-9P
131676-75-0P 131676-77-2P 131676-78-3P, N-(2-
Morpholinophenyl)acetamide 131676-79-4P, N-(5-Methyl-2-
morpholinophenyl)acetamide 131676-80-7P, N-(2-
Morpholinophenyl)propionamide 131676-81-8P, N-(2-
Morpholinophenyl)butyramide 131676-83-0P, N-(2-
Morpholinophenyl)isobutyramide 131676-85-2P, N-(5-Fluoro-2-
morpholinophenyl)isobutyramide 131676-86-3P, N-(2-
Morpholinophenyl)pentanamide 131676-87-4P, N-(2-
Morpholinophenyl)neopentanamide 131676-88-5P 131676-89-6P
131676-90-9P 131676-91-0P 131676-94-3P 131676-97-6P 131676-98-7P
131676-99-8P 131677-00-4P 131677-01-5P, 4-(2-[1-(2-Cyanoethyl)-2-
piperidinylideneamino]phenyl)morpholine 131677-02-6P,
4-[2-(3-Morpholinylideneamino)phenyl]morpholine hydrochloride
131677-05-9P 131677-06-0P 131677-08-2P, 4-[2-(1,3-Dimethyl-2-
imidazolidinylideneamino)phenyl]morpholine 131677-09-3P 131677-10-6P
131677-11-7P 131677-12-8P 131677-13-9P 131677-14-0P 131677-15-1P
131677-17-3P 131677-18-4P 131677-20-8P 131677-22-0P 131677-23-1P
131677-24-2P 131677-26-4P 131677-28-6P 131677-29-7P 131677-30-0P
131677-31-1P 131677-35-5P 131677-36-6P, 1-Ethyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-37-7P, 1-Allyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-38-8P, 1-Butyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-39-9P, 1-Pentyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-40-2P, 4-(2-[1-Methyl-3-(2-methoxyethyl)-
2-imidazolidinylideneamino]phenyl)morpholine 131677-41-3P,
4-(2-[1-Methyl-3-(2-methoxyethyl)-2-imidazolidinylideneamino]phenyl)morpho-
line monofumarate 131677-42-4P, 4-(2-[1-Methyl-3-(2-hydroxyethyl)-2-
imidazolidinylideneamino]phenyl)morpholine 131677-43-5P,
N,N-Dimethyl-N'-(2-morpholinophenyl)morpholine-4-formamide
131677-44-6P 131677-45-7P, 4-[2-(1,3-Dimethyl-2-
imidazolidinylideneamino)phenyl]thiamorpholine 1-oxide 131677-46-8P,
4-[2-(2-Imidazolidenylideneamino)phenyl]morpholine 131677-47-9P,
4-[2-(1-Methyl-2-imidazolidinylideneamino)phenyl]morpholine 131677-48-0P
131677-49-1P 131677-50-4P 131677-51-5P 131677-52-6P 131677-53-7P
131677-54-8P 131677-55-9P 131677-56-0P 131677-58-2P 131677-59-3P
131677-60-6P 131677-61-7P 131677-62-8P 131677-63-9P 131677-64-0P
131677-65-1P 131677-66-2P 131677-67-3P 131677-68-4P 131677-69-5P
131677-70-8P 131677-71-9P 131677-72-0P 131677-73-1P 131677-74-2P
131677-75-3P 131677-76-4P 131677-77-5P 131677-78-6P 131677-79-7P
131677-80-0P 131677-81-1P, 4-[2-(4-Methyl-2-
imidazolidinylideneamino)phenyl]morpholine 131677-82-2P,
4-[2-(4,5-Dimethyl-2-imidazolidinylideneamino)phenyl]morpholine
131677-83-3P, 4-[2-(4,5-Dimethyl-1-(2-hydroxyethyl)-2-
imidazolidinylideneamino)phenyl]morpholine 131677-84-4P,
4-[2-(1-Methylperhydropyrimidin-2-ylideneamino)phenyl]morpholine
131677-85-5P, 2-(2-Morpholinophenylimino)-1,3-diazacycloheptane
131677-86-6P, 1,1-Dimethyl-2-(morpholinophenyl)guanidine 131677-87-7P,
1,3-Dimethyl-2-(morpholinophenyl)guanidine 131677-88-8P,
1,3,3-Trimethyl-2-(2-morpholinophenyl)guanidine 131677-89-9P,
1-Ethyl-2-(2-morpholinophenyl)-3-methylguanidine 131677-90-2P,
1,3-Diethyl-2-(2-morpholinophenyl)guanidine 131677-91-3P,
4-(2-[1-(2-Acetoxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine
131677-93-5P, 1-Butyl-2-(2-morpholinophenyl)-3-methylguanidine
131677-94-6P, 1-(2-Methoxyethyl)-2-(2-morpholinophenyl)guanidine
131677-96-8P, 1-(2-Methylthioethyl)-2-(2-morpholinophenyl)guanidine
131677-97-9P 131677-98-0P, 1-Propyl-2-morpholinophenyl-3-methylguanidine
monofumarate 131677-99-1P, 1-Methyl-2-(2-morpholinophenyl)-3-(2-
methoxyethyl)guanidine 131678-01-8P, 1-Cyclopentyl-2-(2-
morpholinophenyl)-3-methylguanidine 131678-02-9P, 1-Cyclohexyl-2-(2-
morpholinophenyl)-3-methylguanidine monofumarate 131678-03-0P,
N-Methyl-N'-(2-morpholinophenyl)pyrrolidine-1-formamide 131678-08-5P,

1,3-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine fumarate
 131678-09-6P, 4-(2-[1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]-4-methylphenyl)morpholine 131678-12-1P, 1-Butyl-2-(5-methyl-2-morpholinophenyl)-3-methylguanidine 131678-13-2P 131678-14-3P
 131678-15-4P 131678-16-5P 131678-17-6P 131678-18-7P 131678-19-8P,
 1,1-Dimethyl-2-(5-cyano-2-morpholinophenyl)guanidine 131678-20-1P,
 1,3-Dipropyl-2-(2-morpholinophenyl)guanidine 131678-21-2P,
 1,3-Dipropyl-2-(2-morpholinophenyl)guanidine hemifumarate 131678-22-3P
 131678-23-4P 131678-24-5P 131678-25-6P 131678-26-7P 131678-27-8P
 131678-28-9P 131678-29-0P 131678-30-3P 131678-31-4P 131678-32-5P
 131678-33-6P 131678-35-8P 131678-36-9P 131678-38-1P 131678-39-2P
 131678-40-5P 131678-41-6P 131678-43-8P 131678-44-9P 131678-45-0P
 131678-46-1P, 1,1-Dimethyl-2-(5-methoxycarbonyl-2-morpholinophenyl)guanidine 131678-47-2P 131678-48-3P 131678-49-4P
 131678-50-7P 131678-51-8P 131678-52-9P 131678-53-0P 131678-54-1P
 131678-55-2P 131678-56-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as hypoglycemic)

IT

131678-57-4P 131678-58-5P 131678-59-6P, 1,1-Dimethyl-2-(5-chloro-2-morpholinophenyl)guanidine 131678-60-9P, 1,1-Dimethyl-2-(5-fluoro-2-morpholinophenyl)guanidine 131678-61-0P, 1,1-Dimethyl-2-(3-methyl-2-morpholinophenyl)guanidine 131678-62-1P, 1,1-Dimethyl-2-(5-isobutyl-2-morpholinophenyl)guanidine 131678-63-2P, 1,1-Dimethyl-2-(5-methylsulfinyl-2-morpholinophenyl)guanidine 131678-64-3P 131678-65-4P
 131678-66-5P 131678-67-6P 131678-70-1P 131678-71-2P 131678-72-3P,
 4-(2-[1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine monotartrate 131678-74-5P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine monotartrate 131678-75-6P, 1,1-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine monohydrochloride 131678-76-7P,
 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine monohydrochloride 131678-78-9P, 4-[4-Chloro-2-(1,3-dimethyl-2-imidazolidinylideneamino)benzyl]morpholine 131678-79-0P, 4-[4-Chloro-2-(1,3-dimethyl-2-imidazolidinylideneamino)benzyl]morpholine monofumarate 131678-80-3P,
 N-(2-Morpholinomethylphenyl)morpholine-4-formamidinium 131678-81-4P,
 N-(2-Morpholinophenyl)neopentanamide monofumarate 131678-84-7P,
 N-Methyl-N'-(2-morpholinomethylphenyl)neopentanamide 131678-85-8P,
 4-(2-[1-(2-Benzoyloxyethyl)-3-methyl-2-imidazolidinylideneamino]phenyl)morpholine 131678-87-0P, 4-[2-(1-Isopropyl-4,4-dimethyl-2-imidazolidinylideneamino)phenyl]morpholine 131678-88-1P,
 1-(2-Methoxyethyl)-2-(2-morpholinophenyl)guanidine fumarate 131678-89-2P, N-Methyl-N'-(2-morpholinophenyl)pyrrolidine-1-formamidinium monofumarate 131678-90-5P, 1-Butyl-2-(2-morpholinophenyl)-3-ethylguanidine monofumarate 131678-92-7P, 1-Butyl-2-(5-methyl-2-morpholinophenyl)-3-methylguanidine monofumarate 131678-93-8P,
 1-Butyl-2-(6-methyl-2-morpholinophenyl)-3-methylguanidine 131678-94-9P,
 1-Butyl-2-(6-methyl-2-morpholinomethyl)-3-methylguanidine monofumarate 131678-95-0P, 1,1-Dimethyl-2-(2-morpholino-5-trifluoromethylphenyl)guanidine fumarate 131678-96-1P, 1,1-Dimethyl-2-(5-cyano-2-morpholinophenyl)guanidine monofumarate 131678-98-3P,
 1,1-Dimethyl-2-(5-chloro-2-morpholinophenyl)guanidine monofumarate 131678-99-4P, 1,1-Dimethyl-2-(5-fluoro-2-morpholinophenyl)guanidine fumarate 131679-00-0P, 1,1-Dimethyl-2-(3-methyl-2-morpholinophenyl)guanidine fumarate 131679-01-1P, N,N-Dimethyl-N'-(2-morpholinomethylphenyl)guanidine 131679-03-3P, 4-[2-(1-Benzyl-3-methyl-2-pyrrolidinylideneamino)phenyl]morpholine 131679-07-7P,
 4-(2-[1-Methyl-3-(2-acetoxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine 131679-37-3P, 1-Butyl-3-(5-chloro-2-morpholinophenyl)thiourea 131679-38-4P 131679-40-8P 131679-42-0P 131679-45-3P,
 1,1-Dimethyl-2-(2-morpholinophenyl)thiourea 131679-46-4P,
 2-Methyl-1-(2-morpholinophenyl)-3,3-dimethyl-2-thiopseudourea 131697-93-3P 131697-94-4P 131697-95-5P 131697-96-6P 131697-97-7P
 131697-98-8P 131697-99-9P, 4-[2-(1-Isopropyl-4,4-dimethyl-2-imidazolidinylideneamino)phenyl]morpholine monofumarate 131698-00-5P

131698-01-6P 131698-02-7P, 1,1-Dimethyl-2-(4-methoxy-2-morpholinophenyl)guanidine 143803-94-5P 143803-95-6P 143803-96-7P
 143803-99-0P 143804-00-6P 143804-01-7P 143804-02-8P 143804-03-9P,
 N-(2-Morpholinomethyl)butyramidine 143804-04-0P, N-(5-Methylthio-2-morpholinophenyl)isobutyramidine 143804-05-1P, 4-[2-(3-Morpholinylideneamino)phenyl]morpholine 143804-06-2P 143804-07-3P
 143804-08-4P, 2-(2-Morpholinomethyl)-1,1,3,3-tetramethylguanidine
 143804-09-5P, 4-(2-[1-(2-Formyloxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine 143804-10-8P, 1-(2-Methoxyethyl)-2-(2-piperidinylphenyl)guanidine 143804-11-9P, 1-Methyl-3-[2-(1-pyrrolidinyl)phenyl]urea 143804-12-0P, 1-Methyl-3-(5-methyl-2-morpholinophenyl)urea 143804-13-1P, 1-Methyl-2-(2-morpholinophenyl)-3-pentylguanidine 143804-14-2P 143804-15-3P 143804-16-4P,
 4-[2-(1,3-Dimethyl-2-imidazolidinylideneamino)benzyl]morpholine
 144187-06-4P, 4-[2-(2-Piperidinylideneamino)phenyl]morpholine maleate
 144187-07-5P 144187-08-6P 144187-09-7P 144187-11-1P 144187-12-2P
 144187-13-3P 144187-14-4P, 1,1-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine monotartrate 144187-15-5P,
 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine hemisulfate 144187-16-6P,
 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine hemipamoate 144187-17-7P,
 N-(2-Morpholinomethyl)butyramidine fumarate 144187-19-9P,
 N-Methyl-N'-(2-morpholinomethylbenzyl)neopentanamide monofumarate
 144187-20-2P, 4-(2-[1-(2-Benzoyloxyethyl)-3-methyl-2-imidazolidinylideneamino]phenyl)morpholine monofumarate 144187-21-3P
 144187-22-4P, 1,3,3-Trimethyl-2-(2-morpholinophenyl)guanidine monofumarate
 144187-23-5P, 1-Butyl-2-(2-morpholinophenyl)-3-methylguanidine monofumarate 144187-24-6P, 1-(2-Methoxyethyl)-2-(2-piperidinophenyl)guanidine hemifumarate 144187-25-7P,
 1-Methyl-2-(2-morpholinophenyl)-3-(2-methoxyethyl)guanidine hemifumarate
 144187-26-8P, 1-Allyl-2-[2-(1-pyrrolidinyl)phenyl]-3-methylguanidine monofumarate 144187-27-9P, 4-[2-[1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]-4-methylphenyl]morpholine.2/3 fumarate
 144187-28-0P, 1-Methyl-2-(2-morpholinophenyl)-3-valeramide monofumarate
 144187-29-1P, 2-Methyl-1-(6-methyl-2-morpholinophenyl)-3-methyl-2-thiopseudourea hydriodide 144187-32-6P, N,N-Dimethyl-N'-(2-morpholinomethylphenyl)guanidine monofumarate


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as hypoglycemic)

IT 80-73-9P, 1,3-Dimethyl-2-imidazolidinone 1530-89-8P, 4-Cyanomorpholine
 3699-54-5P, 1-(2-Hydroxyethyl)-2-imidazolidinone 51317-68-1P,
 2-Piperidinophenyl isothiocyanate 67829-55-4P, 1-[2-(1-Pyrrolidinyl)phenyl]urea 95539-61-0P, 4-(2-Aminobenzyl)morpholine
 131679-04-4P 131679-05-5P 131679-06-6P 131679-08-8P,
 1-[2-(4-Morpholino)phenyl]thiourea 131679-09-9P 131679-12-4P
 131679-13-5P, 2-[Bis(2-methoxyethyl)amino]phenyl isothiocyanate
 131679-14-6P 131679-15-7P 131679-16-8P, 2-Thiamorpholinophenyl isothiocyanate 131679-18-0P 131679-21-5P 131679-22-6P,
 5-Methyl-2-morpholinophenyl isothiocyanate 131679-23-7P,
 1-(5-Methyl-2-morpholinophenyl)thiourea 131679-24-8P,
 1-[2-(2-Methyl-1-pyrrolidinyl)phenyl]thiourea 131679-25-9P
 131679-26-0P, 1-(2-Piperidinophenyl)thiourea 131679-27-1P
 131679-28-2P, 6-Methyl-2-piperidinophenyl isocyanate 131679-29-3P
 131679-30-6P, N-(2-Hydroxyethyl)-1,2-dimethyl-1,2-ethylenediamine
 131679-31-7P, 1-(2-Morpholinophenyl)-3-methylthiourea 131679-32-8P,
 2-Methyl-1-(2-morpholinophenyl)guanidine 131679-36-2P 131679-44-2P
 131679-50-0P 131679-52-2P 131679-53-3P 131679-54-4P 131679-55-5P
 131679-56-6P 131679-57-7P 131679-58-8P 131679-59-9P 131679-60-2P
 131679-61-3P 131679-62-4P 131679-63-5P 131679-64-6P,
 N-(2-Morpholinophenyl)-N-cyanoamine 131679-65-7P, N-Methyl-N'-(2-morpholinophenyl)carbodiimide 131679-66-8P 131679-67-9P
 131698-05-0P, 1-(6-Methyl-2-piperidinophenyl)thiourea 131698-06-1P
 144187-33-7P, 6-Methyl-2-morpholinophenyl isothiocyanate 144187-34-8P,
 1-(6-Methyl-2-morpholinophenyl)urea 144187-36-0P, 1-(2-

Thiamorpholinophenyl)urea 144187-37-1P, 3-Benzoyl-1-[2-(1-pyrrolidinyl)phenyl]urea 144187-38-2P 144187-39-3P,
 1-Ethyl-3-(2-morpholinophenyl)urea 144187-40-6P 144187-41-7P,
 1-Butyl-3-(2-morpholinophenyl)pseudourea 144187-58-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)

- (prepn. of, as intermediate for hypoglycemics)
- IT 57-13-6, Urea, reactions 74-88-4, Methyl iodide, reactions 75-21-8, Oxirane, reactions 78-82-0, Isobutyronitrile 80-48-8, Methyl p-toluenesulfonate 93-97-0, Benzoyl anhydride 107-15-3, 1,2-Ethanediamine, reactions 109-11-5, 3-Morpholinone 109-73-9, Butylamine, reactions 109-74-0, Butyronitrile 109-81-9 110-59-8, Valeronitrile 110-60-1, 1,4-Butanediamine 111-41-1, N-(2-Hydroxyethyl)-1,2-ethylenediamine 124-40-3, Dimethylamine, reactions 130-85-8, Pamoic acid 463-71-8, Thiophosgene 532-55-8, Benzoyl isothiocyanate 556-61-6, Methyl isothiocyanate 563-86-0, 1,2-Dimethylethylenediamine 592-82-5, Butyl isothiocyanate 630-18-2 632-22-4, Tetramethylurea 675-20-7, 2-Piperidinone 784-57-6, 2-Morpholino-5-(trifluoromethyl)aniline 872-50-4, 1-Methyl-2-pyrrolidinone, reactions 1003-03-8, Cyclopentylamine 1467-79-4, N,N-Dimethylcyanamide 5370-33-2, 1,3,3-Trimethyl-2-pyrrolidinone 5448-29-3, N'-Isopropyl-2-methyl-1,2-propanediamine 5585-33-1 6291-84-5, 3-(Methylamino)propylamine 6830-83-7 21627-58-7, 1-(2-Aminophenyl)pyrrolidine 22455-69-2 26586-18-5, 4-(2-Amino-4-methoxycarbonylphenyl)morpholine 39643-31-7, 2-Piperidinoaniline 39799-78-5, 1,3-Dimethyl-2-imidazolinone 50533-97-6, 4-(Dimethylamino)piperidine 51317-67-0 59504-49-3 84186-31-2, 6-Methyl-2-piperidinoaniline 90875-44-8, 4-(2-Amino-4-chlorophenyl)morpholine 91429-92-4, 4-(2-Amino-4-methylphenyl)morpholine 108303-99-7, 1-Benzyl-3-methyl-2-pyrrolidinone 113502-25-3, 3-Ethyl-1,1,3-trimethylurea 131679-48-6, 2-Morpholino-5-(trimethylmethyl)phenyl isothiocyanate 131679-49-7 144187-42-8, 1-Methyl-3-(2-methoxyethyl)-2-piperidinone 144187-43-9, 5-(Methylthio)-2-morpholinoaniline 144187-44-0, 5-Fluoro-2-morpholinoaniline 144187-45-1, 4-(2-Amino-4-chlorobenzyl)morpholine 144187-46-2, 3-Allyl-2-(2-morpholinophenyl)-1,3,3-trimethylurea 144187-47-3, 3-Butyl-1,1,3-trimethylurea 144187-48-4 144187-50-8, 6-Methyl-2-morpholinoaniline 144187-51-9, N,N-Bis(2-methoxyethyl)benzene-1,2-diamine 144187-52-0, 2-Thiomorpholinoaniline 144187-53-1, 2-Methyl-1-(2-aminophenyl)pyrrolidine 144187-54-2 144187-55-3, 4-(2-Aminophenyl)morpholine hydrochloride 144187-56-4, 4-Methoxy-2-morpholinoaniline 144187-57-5, 5-Isobutyl-2-morpholinoaniline hydrochloride
 RL: RCT (Reactant)
 (reaction of, in prepn. of hypoglycemics)
- IT 130-85-8, Pamoic acid
 RL: RCT (Reactant)
 (reaction of, in prepn. of hypoglycemics)
- RN 130-85-8 HCAPLUS
- CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA INDEX NAME)



L76 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 AN 1991:598202 HCAPLUS
 DN 115:198202
 TI Effect of the lysosomotropic drug suramin on islet lysosomal enzyme activities and the insulin-secretory response induced by various secretagogues
 AU Panagiotidis, Georgios; Salehi, Albert A.; Lundquist, Ingmar
 CS Fac. Health Sci., Univ. Linköping, Linköping, S-581 85, Swed.
 SO Pharmacology (1991), 43(3), 163-8
 CODEN: PHMGBN; ISSN: 0031-7012
 DT Journal
 LA English
 CC 1-10 (Pharmacology)
 AB The trypanocidal drug suramin is known to conc. in lysosomes and to depress the activity of different lysosomal enzymes. The authors have shown previously that suramin can inhibit the activity of the islet lysosomal enzyme acid amyloglucosidase, a glycogenolytic glucose-producing hydrolase, which seems to be involved in certain insulin-secretory processes. In the present investigation they studied the pH dependency and dose-response effects of suramin on islet lysosomal enzyme activities as well as the effect of suramin treatment on the insulin-secretory response to various secretagogues in mice. It was found that two injections of suramin (0.18 mmol/kg) to normal NMRI mice at -24 and -2 h induced a moderate depression of the activities of islet acid amyloglucosidase (-22%) and acid phosphatase (-13%), whereas no effect was recorded for the activities of acid .alpha.-glucosidase, N-acetyl-.beta.-D-glucosaminidase and the non-lysosomal enzyme neutral .alpha.-glucosidase. Direct addn. of different concns. of suramin to islet homogenates showed that the drug was a potent inhibitor of acid amyloglucosidase and acid .alpha.-glucosidase at pH 4.0. At pH 5.0, suramin induced a large increase in acid .alpha.-glucosidase activity, whereas acid amyloglucosidase and acid phosphatase were inhibited. Suramin-injected mice showed a reduced insulin-secretory response to the sulfonylurea drug glibenclamide (-45%), whereas the insulin response to the cholinergic agonist carbachol or the phosphodiesterase inhibitor IBMX (1-isobutyl-3-methylxanthine) was unaffected. Thus, suramin inhibits islet acid amyloglucosidase activity in vivo and in vitro, whereas its effect on acid .alpha.-glucosidase is complex and pH dependent. The inhibitory effect of suramin on the glibenclamide-stimulated insulin response lends further support to the hypothesis that islet amyloglucosidase is involved in sulfonylurea-induced insulin secretion.
 ST suramin pancreatic islet enzyme insulin secretion
 IT Pancreatic islet of Langerhans
 (lysosomal enzymes of, suramin effect on, insulin secretion in relation to)
 IT Lysosome
 (of pancreatic islets of Langerhans, enzymes of, suramin effect on, insulin secretion in relation to)

IT Sulfonamides
 RL: BIOL (Biological study)
 (sulfonylureas, insulin secretion induced by, suramin effect on, lysosomal enzymes in relation to)

IT 51-83-2 1023-21-8 28822-58-4
 RL: BIOL (Biological study)
 (insulin secretion induced by, suramin effect on, lysosomal enzymes in relation to)

IT 9001-77-8, Acid phosphatase 9012-33-3 9032-08-0, Amyloglucosidase 9033-06-1, Glucosidase
 RL: BIOL (Biological study)
 (of lysosomes, of pancreatic islets of Langerhans, suramin effect on, insulin secretion in relation to)


IT 145-63-1, Suramin
 RL: BIOL (Biological study)
 (pancreatic islet of Langerhans lysosomal enzyme activities response to, insulin-secretory response to secretagogues in relation to)

IT 9004-10-8, Insulin, biological studies
 RL: BIOL (Biological study)
 (secretion of, secretagogue-induced, suramin effect on, lysosomal enzymes in relation to)


IT 145-63-1, Suramin
 RL: BIOL (Biological study)
 (pancreatic islet of Langerhans lysosomal enzyme activities response to, insulin-secretory response to secretagogues in relation to)

RN 145-63-1 HCAPLUS
 CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 9004-10-8, Insulin, biological studies
 RL: BIOL (Biological study)
 (secretion of, secretagogue-induced, suramin effect on, lysosomal
 enzymes in relation to)
 RN 9004-10-8 HCAPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 AN 1991:400778 HCAPLUS
 DN 115:778
 TI Covalently-linked complexes and methods for enhanced cytotoxicity and
 imaging
 IN Anderson, David C.; Morgan, A. Charles; Abrams, Paul G.; Nichols, Everett
 J.; Fritzberg, Alan R.
 PA NeoRx Corp., USA
 SO Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM A61K047-00
 ICS A61K049-02; A61K043-00
 CC 1-6 (Pharmacology)
 Section cross-reference(s): 8, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 359347	A2	19900321	EP 1989-250014	19890814
	EP 359347	A3	19900418		
	EP 359347	B1	19921223		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5135736	A	19920804	US 1988-232337	19880815
	US 5169933	A	19921208	US 1989-390241	19890807
	CA 1334513	A1	19950221	CA 1989-608198	19890811
	JP 02124833	A2	19900514	JP 1989-209992	19890814
	AT 83669	E	19930115	AT 1989-250014	19890814
PRAI	US 1988-232337		19880815		
	EP 1989-250014		19890814		

AB Covalently-linked complexes (CLCs) for targeting a defined population of
 cells comprise a targeting protein (e.g. antibody, hormone, enzyme, etc.),
 a cytotoxic agent (e.g. radionuclide, toxin, drug, etc.) an enhancing
 moiety capable of enhancing CLC-target cell interaction (e.g. a
 translocating/internalizing moiety, an anchoring peptide, membrane-sol.
 hydrophobic mol., etc.). The CLCs are used to enhance in vivo
 cytotoxicity and imaging (no data). Translocating peptide,
 Cys-Gly-Glu-Ala-Ala-Leu-Ala(Glu-Ala-Leu-Ala)4-Glu-Ala-Leu-Glu-Ala-Leu-Ala-
 Ala-NH₂, is conjugated via succinimidyl 4(N-maleimidemethyl)cyclohexane-1-

- carboxylate (SMCC) to reduced toxin A chain. The conjugate is reacted with iminothiolane to generate further thiol groups which are then bonded to reduced antibody to prep. translocating peptide-ricin A chain-antibody CLC.
- ST targeting protein cytotoxin enhancer conjugate; translocating peptide ricin antibody conjugate; imaging radionuclide targeting protein enhancer conjugate
- IT Animal cell
(agents enhancing covalently-linked complex interaction with, conjugates with cytotoxic agent and targeting protein)
- IT Clathrins
RL: BIOL (Biological study)
(antibodies to, conjugates with cytotoxic agent and targeting protein)
- IT Antigens
RL: BIOL (Biological study)
(antibody to binding region of, conjugates with cytotoxic agent and target cell interaction enhancers)
- IT Pokeweed
(antiviral proteins of, conjugates with targeting protein and target cell interaction enhancer)
- IT Antibodies
RL: BIOL (Biological study)
(as targeting protein in conjugates with cytotoxic agent and target cell interaction enhancers)
- IT Anesthetics
Animal growth regulators
RL: BIOL (Biological study)
(conjugates with cytotoxic agent and targeting protein)
- IT Cytotoxic agents
Fluorescent substances
Pharmaceuticals
Toxins
RL: BIOL (Biological study)
(conjugates with targeting protein and target cell interaction enhancer)
- IT Pseudomonas
(exotoxin A of, conjugates with targeting protein and target cell interaction enhancer)
- IT Virus
(fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
- IT Membrane, biological
(mol. sol. in, conjugates with cytotoxic agent and targeting protein)
- IT Venoms
(peptides of, of snake, conjugates with targeting protein and target cell interaction enhancer)
- IT Barley
(toxins of, conjugates with targeting protein and target cell interaction enhancer)
- IT Snake
(venom peptides of, conjugates with targeting protein and target cell interaction enhancer)
- IT Radioelements, compounds
RL: BIOL (Biological study)
(Auger electron-emitting, conjugates, with targeting protein and target cell interaction enhancer)
- IT Virus, animal
(Sendai, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
- IT Toxins
RL: BIOL (Biological study)
(Shiga, conjugates with targeting protein and target cell interaction enhancer)

- IT Radioelements, compounds
RL: BIOL (Biological study)
(X-ray-emitting, conjugates, with targeting protein and target cell interaction enhancer)
- IT Radioelements, compounds
RL: BIOL (Biological study)
(alpha-particle-emitting, conjugates, with targeting protein and target cell interaction enhancer)
- IT Fatty acids, compounds
RL: BIOL (Biological study)
(analogs, conjugates, with cytotoxic agent and targeting protein)
- IT Proteins, specific or class
RL: BIOL (Biological study)
(antiviral, of pokeweed, conjugates with targeting protein and target cell interaction enhancer)
- IT Lipoproteins
RL: BIOL (Biological study)
(apo-, A-I, conjugates, with cytotoxic agent and targeting protein)
- IT Lipoproteins
RL: BIOL (Biological study)
(apo-, B, conjugates, with cytotoxic agent and targeting protein)
- IT Radioelements, compounds
RL: BIOL (Biological study)
(beta-particle-emitting, conjugates, with targeting protein and target cell interaction enhancer)
- IT Avidins
Enzymes
Peptides, compounds
RL: BIOL (Biological study)
(conjugates, with cytotoxic agent and target cell interaction enhancers, for cell targeting for enhanced cytotoxicity)
- IT Bile acids
Estrogens
Fatty acids, compounds
Phospholipids, compounds
Transferrins
RL: BIOL (Biological study)
(conjugates, with cytotoxic agent and targeting protein)
- IT Leupeptins
Phosphatidylinositols
RL: BIOL (Biological study)
(conjugates, with cytotoxic agent and targeting protein, cell targeting with, for enhanced cytotoxicity and imaging)
- IT Abrins
Radioelements, compounds
Ricins
RL: BIOL (Biological study)
(conjugates, with targeting protein and target cell interaction enhancer)
- IT Radiography
Scintigraphy
Tomography
(contrast agents, covalently linked complexes contg. cytotoxic agent and targeting protein and enhancing moiety as)
- IT Toxins
RL: BIOL (Biological study)
(cyto-, conjugates with targeting protein and target cell interaction enhancer)
- IT Toxins
RL: BIOL (Biological study)
(diphtheria, conjugates with targeting protein and target cell interaction enhancer)
- IT Toxins

- RL: BIOL (Biological study)
(exo-, A, of Pseudomonas, conjugates with targeting protein and target cell interaction enhancer)
- IT Proteins, specific or class
RL: BIOL (Biological study)
(fusion products, conjugates, with cytotoxic agent and targeting protein)
- IT Carbohydrates and Sugars, compounds
RL: BIOL (Biological study)
(galactose-contg., conjugates, with cytotoxic agent and targeting protein)
- IT Radioelements, compounds
RL: BIOL (Biological study)
(gamma-ray-emitting, conjugates, with targeting protein and target cell interaction enhancer)
- IT Ribonucleic acid formation factors
RL: BIOL (Biological study)
(gene tat, conjugates with cytotoxic agent and targeting protein)
- IT Carbohydrates and Sugars, compounds
RL: BIOL (Biological study)
(glucose-contg., conjugates, with cytotoxic agent and targeting protein)
- IT Virus, animal
(human immunodeficiency, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
- IT Virus, animal
(measles, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
- IT Glycerides, compounds
RL: BIOL (Biological study)
(medium-chain, conjugates, with cytotoxic agent and targeting protein)
- IT Antibodies
RL: SPN (Synthetic preparation); PREP (Preparation)
(monoclonal, conjugates with chelated radiolabel and anchoring peptide, prepn. of, for cell targeting)
- IT Virus, animal
(murine mammary tumor, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
- IT Toxins
RL: BIOL (Biological study)
(pertussis, conjugates with targeting protein and target cell interaction enhancer)
- IT Proteins, specific or class
RL: BIOL (Biological study)
(pore-forming, conjugates, with cytotoxic agent and targeting protein)
- IT Radioelements, compounds
RL: BIOL (Biological study)
(positron-emitting, conjugates, with targeting protein and target cell interaction enhancer)
- IT Virus, animal
(respiratory syncytial, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
- IT Proteins, specific or class
RL: BIOL (Biological study)
(saporins, conjugates, with targeting protein and target cell interaction enhancer)
- IT Peptides, compounds
RL: BIOL (Biological study)
(signal, conjugates, with cytotoxic agent and targeting protein)
- IT Virus, animal
(simian immunodeficiency, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
- IT Virus, animal

- (simian retro-, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
- IT Biological transport
(translocation, agents for, conjugates with cytotoxic agent and targeting protein)
- IT Proteins, specific or class
RL: BIOL (Biological study)
(tritins, conjugates, with targeting protein and target cell interaction enhancer)
- IT Virus, animal
(visna, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
- IT Hemolysins
RL: BIOL (Biological study)
(.delta.-, conjugates, with cytotoxic agent and targeting protein)
- IT Carbohydrates and Sugars, compounds
RL: BIOL (Biological study)
(N-acetylglucosamine-contg., conjugates, with cytotoxic agent and targeting protein)
- IT 50-18-0D, Cyclophosphamide, conjugates with targeting protein and target cell interaction enhancer 51-21-8D, 5-Fluorouracil, conjugates with targeting protein and target cell interaction enhancer 54-42-2D, Iododeoxyuridine, conjugates with targeting protein and target cell interaction enhancer 56-81-5D, 1,2,3-Propanetriol, conjugates with cytotoxic agent and targeting protein 59-05-2D, Methotrexate, conjugates with targeting protein and target cell interaction enhancer 59-43-8D, Thiamine, conjugates with cytotoxic agent and targeting protein 66-72-8D, Pyridoxal, conjugates with cytotoxic agent and targeting protein 79-83-4D, Pantothenic acid, conjugates with cytotoxic agent and targeting protein 112-79-8D, Elaidic acid, conjugates with cytotoxic agent and targeting protein 123-39-7D, N-Methylformamide, conjugates with targeting protein and target cell interaction enhancer 128-13-2D, Ursodeoxycholic acid, conjugates with cytotoxic agent and targeting protein 133-89-1D, UDP-glucose, conjugates with cytotoxic agent and targeting protein 135-16-0D, conjugates with cytotoxic agent and targeting protein 137-58-6D, Lidocaine, conjugates with cytotoxic agent and targeting protein 145-63-1D, Suramin, conjugates with targeting protein and target cell interaction enhancer 147-94-4D, Cytarabine, conjugates with targeting protein and target cell interaction enhancer 148-82-3D, Melphalan, conjugates with targeting protein and target cell interaction enhancer 154-42-7D, 6-Thioguanine, conjugates with targeting protein and target cell interaction enhancer 320-67-2D, Azacitidine, conjugates with targeting protein and target cell interaction enhancer 459-86-9D, Mitoguanzone, conjugates with targeting protein and target cell interaction enhancer 474-25-9D, Chenodeoxycholic acid, conjugates with cytotoxic agent and targeting protein 512-64-1D, Echinomycin, conjugates with targeting protein and target cell interaction enhancer 528-04-1D, conjugates with cytotoxic agent and targeting protein 528-74-5D, Dichloromethotrexate, conjugates with targeting protein and target cell interaction enhancer 544-63-8D, Tetradecanoic acid, conjugates with cytotoxic agent and targeting protein 645-05-6D, Hexamethylmelamine, conjugates with targeting protein and target cell interaction enhancer 693-72-1D, trans-Vaccenic acid, conjugates with cytotoxic agent and targeting protein 865-21-4D, Vinblastine, conjugates with targeting protein and target cell interaction enhancer 2956-16-3D, UDP-galactose, conjugates with cytotoxic agent and targeting protein 3063-71-6D, conjugates with cytotoxic agent and targeting protein 3375-50-6D, conjugates with targeting protein and target cell interaction enhancer 3616-06-6D, UDP-xylose, conjugates with cytotoxic agent and targeting protein 3672-15-9D, Mannose-6-phosphate, conjugates with cytotoxic agent and targeting protein 3778-73-2D, Ifosfamide, conjugates with targeting protein and target cell interaction enhancer 4005-51-0D, 2-Amino-1,3,4-thiadiazole, conjugates with targeting protein and target

cell interaction enhancer 6082-29-7D, conjugates with cytotoxic agent and targeting protein 6990-06-3D, Fusidic acid, conjugates with cytotoxic agent and targeting protein 7440-16-6D, Rhodium, conjugates with targeting protein and target cell interaction enhancer 7481-89-2D, Dideoxycytidine, conjugates with targeting protein and target cell interaction enhancer 9002-64-6D, Parathyroid hormone, conjugates with cytotoxic agent and targeting protein 9004-10-8D, Insulin, conjugates with cytotoxic agent and targeting protein 9007-12-9D, Calcitonin, conjugates with cytotoxic agent and targeting protein 9007-92-5D, Glucagon, conjugates with cytotoxic agent and targeting protein 9015-68-3D, Asparaginase, conjugates with targeting protein and target cell interaction enhancer 10043-49-9D, Gold-198, conjugates with targeting protein and target cell interaction enhancer 10043-66-0D, Iodine-131, conjugates with targeting protein and target cell interaction enhancer 10098-91-6D, Yttrium-90, conjugates with targeting protein and target cell interaction enhancer 10318-26-0D, Dibromodulcitol, conjugates with targeting protein and target cell interaction enhancer 11056-06-7D, Bleomycin, conjugates with targeting protein and target cell interaction enhancer 13494-90-1D, Gallium nitrate, conjugates with targeting protein and target cell interaction enhancer 13551-87-6D, Misonidazole, conjugates with targeting protein and target cell interaction enhancer 13909-02-9D, 1-(2-Chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea, conjugates with targeting protein and target cell interaction enhancer 13909-09-6D, Semustine, conjugates with targeting protein and target cell interaction enhancer 13981-22-1D, Nitrogen-13, conjugates with targeting protein and target cell interaction enhancer 13981-25-4D, Copper-64, conjugates with targeting protein and target cell interaction enhancer 13981-51-6D, Mercury-197, conjugates with targeting protein and target cell interaction enhancer 13981-56-1D, Fluorine-18, conjugates with targeting protein and target cell interaction enhancer 13982-43-9D, Oxygen-15, conjugates with targeting protein and target cell interaction enhancer 14119-09-6D, Gallium-67, conjugates with targeting protein and target cell interaction enhancer 14158-31-7D, Iodine-125, conjugates with targeting protein and target cell interaction enhancer 14333-33-6D, Carbon-11, conjugates with targeting protein and target cell interaction enhancer 14378-26-8D, Rhenium-188, conjugates with targeting protein and target cell interaction enhancer 14378-53-1D, Rhodium-101, conjugates with targeting protein and target cell interaction enhancer 14391-96-9D, Scandium-47, conjugates with targeting protein and target cell interaction enhancer 14687-25-3D, Lead-203, conjugates with targeting protein and target cell interaction enhancer 14769-73-4D, Levamisole, conjugates with targeting protein and target cell interaction enhancer 14809-46-2D, Selenium-72, conjugates with targeting protein and target cell interaction enhancer 14809-47-3D, Bromine-75, conjugates with targeting protein and target cell interaction enhancer 14834-67-4, Iodine-133, biological studies 14834-68-5D, Iodine-135, conjugates with targeting protein and target cell interaction enhancer 14913-49-6D, Bismuth-212, conjugates with targeting protein and target cell interaction enhancer 14914-02-4D, conjugates with targeting protein and target cell interaction enhancer 14914-68-2D, conjugates with targeting protein and target cell interaction enhancer 14981-64-7D, Palladium-109, conjugates with targeting protein and target cell interaction enhancer 14998-63-1D, Rhenium-186, conjugates with targeting protein and target cell interaction enhancer 15092-94-1D, Lead-212, conjugates with targeting protein and target cell interaction enhancer 15411-62-8D, Ruthenium-99, conjugates with targeting protein and target cell interaction enhancer 15663-27-1D, cis-Platinum, conjugates with targeting protein and target cell interaction enhancer 15690-69-4D, Palladium-100, conjugates with targeting protein and target cell interaction enhancer 15715-08-9D, conjugates with targeting protein and target cell interaction enhancer 15741-25-0D, Barium-128, conjugates with targeting protein and target cell interaction enhancer 15750-15-9D, Indium-111, conjugates with targeting protein and target cell interaction enhancer 15755-33-6D, Arsenic-72,

conjugates with targeting protein and target cell interaction enhancer 15755-39-2D, Astatine-211, conjugates with targeting protein and target cell interaction enhancer 15757-14-9D, Gallium-68, conjugates with targeting protein and target cell interaction enhancer 15757-86-5D, Copper-67, conjugates with targeting protein and target cell interaction enhancer 15765-38-5D, Bromine-76, conjugates with targeting protein and target cell interaction enhancer 15765-39-6D, Bromine-77, conjugates with targeting protein and target cell interaction enhancer 15839-70-0D, GDP-fucose, conjugates with cytotoxic agent and targeting protein 16468-59-0D, conjugates with targeting protein and target cell interaction enhancer 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 20449-79-0D, Melittin, conjugates with cytotoxic agent and targeting protein 20537-88-6D, Ethiofos, conjugates with targeting protein and target cell interaction enhancer 22668-01-5D, conjugates with targeting protein and target cell interaction enhancer 23205-42-7D, 3-Deazauridine, conjugates with targeting protein and target cell interaction enhancer 23214-92-8D, Doxorubicin, conjugates with targeting protein and target cell interaction enhancer 23491-44-3D, Pibenzimol, conjugates with targeting protein and target cell interaction enhancer 24584-09-6D, ICRF-187, conjugates with targeting protein and target cell interaction enhancer 26833-87-4D, Homoharringtonine, conjugates with targeting protein and target cell interaction enhancer 27061-78-5D, Alamethicin, conjugates with cytotoxic agent and targeting protein 29767-20-2D, Teniposide, conjugates with targeting protein and target cell interaction enhancer 31312-81-9D, Yttrium-80, conjugates with targeting protein and target cell interaction enhancer 31362-50-2D, Bombesin, conjugates with cytotoxic agent and targeting protein 31441-78-8D, Mercaptopurine, conjugates with targeting protein and target cell interaction enhancer 32954-58-8D, Ipomeanol, conjugates with targeting protein and target cell interaction enhancer 33069-62-4D, Taxol, conjugates with targeting protein and target cell interaction enhancer 41575-94-4D, Carboplatin, conjugates with targeting protein and target cell interaction enhancer 41992-23-8D, Spirogermanium, conjugates with targeting protein and target cell interaction enhancer 42228-92-2D, conjugates with targeting protein and target cell interaction enhancer 51264-14-3D, Amsacrine, conjugates with targeting protein and target cell interaction enhancer 51321-79-0D, PALA, conjugates with targeting protein and target cell interaction enhancer 51348-50-6D, .alpha.-L-Fucose, conjugates with cytotoxic agent and targeting protein 51724-48-2D, Trichothec-9-ene, conjugates with targeting protein and target cell interaction enhancer 52128-35-5D, Trimetrexate, conjugates with targeting protein and target cell interaction enhancer 53910-25-1D, Pentostatin, conjugates with targeting protein and target cell interaction enhancer 54749-90-5D, Chlorozotocin, conjugates with targeting protein and target cell interaction enhancer 56605-16-4D, conjugates with targeting protein and target cell interaction enhancer 57576-44-0D, Aclarubicin, conjugates with targeting protein and target cell interaction enhancer 57998-68-2D, Aziridiny benzoquinone, conjugates with targeting protein and target cell interaction enhancer 59587-18-7D, conjugates with cytotoxic agent and targeting protein 59587-24-5D, conjugates with cytotoxic agent and targeting protein 59653-73-5D, Teroxirone, conjugates with targeting protein and target cell interaction enhancer 59763-91-6D, Pancreatic polypeptide, conjugates with cytotoxic agent and targeting protein 60084-10-8D, Tiazofurin, conjugates with targeting protein and target cell interaction enhancer 60617-12-1D, .beta.-Endorphin, conjugates with cytotoxic agent and targeting protein 61966-08-3D, Triciribine phosphate, conjugates with targeting protein and target cell interaction enhancer 62488-57-7D, conjugates with targeting protein and target cell interaction enhancer 62928-11-4D, Iproplatin, conjugates with targeting protein and target cell interaction enhancer 63521-85-7D, 4'-Deoxydoxorubicin, conjugates with targeting protein and target cell interaction enhancer 65271-80-9D, Mitoxantrone, conjugates with targeting protein and target cell interaction enhancer 65886-71-7D,

Fazarabine, conjugates with targeting protein and target cell interaction enhancer 69111-41-7D, conjugates with cytotoxic agent and targeting protein 69408-81-7D, conjugates with targeting protein and target cell interaction enhancer 70699-67-1D, Paradoxin, derivs., conjugates with cytotoxic agent and targeting protein 71628-96-1D, Menogaril, conjugates with targeting protein and target cell interaction enhancer 73027-21-1D, derivs., conjugates with cytotoxic agent and targeting protein 75607-67-9D, Fludarabine phosphate, conjugates with targeting protein and target cell interaction enhancer 77327-05-0D, Didemnin B, conjugates with targeting protein and target cell interaction enhancer 79152-85-5D, conjugates with targeting protein and target cell interaction enhancer 81424-67-1D, Caracemide, conjugates with targeting protein and target cell interaction enhancer 87626-55-9D, Flavone-8-acetic acid, conjugates with targeting protein and target cell interaction enhancer 89149-10-0D, Deoxyspergualin, conjugates with targeting protein and target cell interaction enhancer 91441-23-5D, conjugates with targeting protein and target cell interaction enhancer 96249-43-3D, conjugates with cytotoxic agent and targeting protein 97534-21-9D, Merbarone, conjugates with targeting protein and target cell interaction enhancer 99278-10-1D, conjugates with cytotoxic agent and targeting protein 103233-04-1D, conjugates with cytotoxic agent and targeting protein 108026-95-5D, conjugates with cytotoxic agent and targeting protein 110064-88-5D, conjugates with cytotoxic agent and targeting protein 131256-61-6D, conjugates with cytotoxic agent and targeting protein 131256-82-1D, conjugates with cytotoxic agent and targeting protein 131256-85-4D, conjugates with cytotoxic agent and targeting protein 131257-09-5D, Bombolittin, conjugates with cytotoxic agent and targeting protein 131399-93-4D, derivs., conjugates with cytotoxic agent and targeting protein 131399-94-5D, conjugates with cytotoxic agent and targeting protein 131399-95-6D, conjugates with cytotoxic agent and targeting protein 131399-96-7D, conjugates with cytotoxic agent and targeting protein 131399-97-8D, conjugates with cytotoxic agent and targeting protein 131399-98-9D, conjugates with cytotoxic agent and targeting protein 131399-99-0D, conjugates with cytotoxic agent and targeting protein 131400-00-5D, conjugates with cytotoxic agent and targeting protein 131400-01-6D, conjugates with cytotoxic agent and targeting protein 131400-02-7D, conjugates with cytotoxic agent and targeting protein 131400-03-8D, conjugates with cytotoxic agent and targeting protein 131400-04-9D, conjugates with cytotoxic agent and targeting protein 131400-05-0D, conjugates with cytotoxic agent and targeting protein 131400-06-1D, conjugates with cytotoxic agent and targeting protein 131400-07-2D, conjugates with cytotoxic agent and targeting protein 131400-08-3D, conjugates with cytotoxic agent and targeting protein

RL: BIOL (Biological study)

(cell targeting with, for enhanced cytotoxicity and imaging)

IT 58-85-5D, Biotin, conjugates with cytotoxic agent and target cell interaction enhancers

RL: BIOL (Biological study)

(for cell targeting for enhanced cytotoxicity and imaging)

IT 14133-76-7D, Technetium-99, conjugates with targeting protein and target cell interaction enhancer

RL: BIOL (Biological study)

(metastable, cell targeting with, for enhanced cytotoxicity and imaging)

IT 96573-46-5 99616-33-8 99896-85-2 110590-64-2

RL: BIOL (Biological study)

(peptides contg., conjugates with cytotoxic agent and targeting protein)

IT 14378-26-8DP, complexes with GABA deriv., conjugates with monoclonal antibody and anchoring peptide 131418-21-8DP, rhenium-188 complexes, conjugates with monoclonal antibody and anchoring peptide

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as radionuclide-targeting protein-anchoring peptide covalently-linked complex for cell targeting)

IT 131400-09-4DP, conjugates with ricin A chain and antibody
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as translocating peptide-targeting protein-cytotoxic agent covalently-linked complex for cell targeting)

IT 544-63-8DP, Tetradecanoic acid, esters
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, for conjugation with antibody fragment and cytotoxic agent)


IT 41191-04-2
 RL: BIOL (Biological study)
 (sol., cell targeting with, for enhanced cytotoxicity and imaging)

IT 65988-88-7D, Modeccin, conjugates 75037-46-6D, Gelonin, conjugates
 RL: BIOL (Biological study)
 (with targeting protein and target cell interaction enhancer)


IT 145-63-1D, Suramin, conjugates with targeting protein and target cell interaction enhancer 9004-10-8D, Insulin, conjugates with cytotoxic agent and targeting protein
 RL: BIOL (Biological study)
 (cell targeting with, for enhanced cytotoxicity and imaging)

RN 145-63-1 HCAPLUS
 CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 9004-10-8 HCAPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2002 ACS

AN 1991:115074 HCAPLUS

DN 114:115074

TI Insulin potentiation therapy (IPT) and pharmaceuticals for viral diseases such as cancers and AIDS

IN Garcia y Bellon, Donato P.; Garcia, Donato P., Jr.; Ayre, Steven G.

PA Mex.

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K037-26

NCL 514003000

CC 1-5 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4971951	A	19901120	US 1987-77833	19870727
	CA 1299102	A1	19920421	CA 1987-539603	19870615
	US 5155096	A	19921013	US 1990-615621	19901119
PRAI	CA 1987-539603		19870615		
	US 1987-77833		19870727		

AB Viral diseases, e.g. cancers and AIDS, are treated by i.v. injection of insulin to induce hypoglycemia and increase cell membrane permeability, followed by parenteral injection of glucose, mixed with or in conjunction with, prescribed antiviral/antineoplastic drugs. Pharmaceutical compns. are also discussed. A patient with AIDS and herpes zoster infection was treated with IPT twice a week in which 6 units insulin were given i.v. After 20 min, 30 mg ribavirin mixed with 50 mL of 50% hypertonic glucose was injected i.v. Antineoplastic drugs, cyclophosphamide 10 and methotrexate 0.5 mg, along with vitamin B complex were concurrently administered. On nontreatment days, the patient took 200 mg ribavirin orally daily, etc. At the end of the 3rd treatment, the herpes zoster had cleared and other symptoms improved. Treatment of various cancers is also described.

ST insulin potentiation therapy virus cancer; AIDS insulin potentiation therapy; herpes zoster insulin potentiation therapy

IT Pharmaceutical dosage forms

(for insulin potentiation therapy of viral infection and cancer)

IT Hypoglycemia

(induction of, with insulin in potentiation therapy of viral infection and cancer)

IT Virus, animal
(infection with, insulin potentiation therapy of)

IT Neoplasm inhibitors
Virucides and Virustats
(potentiation of, with insulin)

IT Sarcoma
(Ewing's, bone, treatment of, insulin potentiation therapy in)

IT Immunodeficiency
(acquired immune deficiency syndrome, treatment of, insulin
potentiation therapy in)

IT Carcinoma
(adeno-, breast infiltrating, treatment of, insulin potentiation
therapy in)

IT Lung, neoplasm
(adenocarcinoma, treatment of, insulin potentiation therapy in)

IT Uterus, neoplasm
(cervix, carcinoma, treatment of, insulin potentiation therapy in)

IT Virus, animal
(human immunodeficiency, infection with herpes zoster and, treatment
of, insulin potentiation therapy in)

IT Virus, animal
(human immunodeficiency 1, infection with herpes zoster and, treatment
of, insulin potentiation therapy in)

IT Pharmaceutical dosage forms
(injections, i.v., for insulin potentiation therapy of viral infection
and cancer)

IT Virus, animal
(varicella-zoster, infection with AIDS virus and, treatment of, insulin
potentiation therapy in)

IT 50-99-7, D-Glucose, biological studies
RL: BIOL (Biological study)
(in insulin potentiation therapy of viral infection and cancer)

IT 50-18-0 51-21-8, 5-Fluorouracil 59-05-2, Methotrexate 145-63-1
, Suramin 30516-87-1 36791-04-5, Ribavirin 89899-81-0, HPA-23
RL: PROC (Process)
(potentiation of, with insulin)


IT 9004-10-8, Insulin, biological studies
RL: BIOL (Biological study)
(potentiation therapy of viral infection and cancer with)

IT 145-63-1, Suramin
RL: PROC (Process)
(potentiation of, with insulin)


RN 145-63-1 HCAPLUS

CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-
phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 9004-10-8, Insulin, biological studies
 RL: BIOL (Biological study)
 (potentiation therapy of viral infection and cancer with)
 RN 9004-10-8 HCAPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 AN 1986:1134 HCAPLUS
 DN 104:1134
 TI Islet lysosomal enzyme activities and plasma insulin levels in obese hyperglycemic mice following injection of the lysosomotropic drug suramin
 AU Lundquist, Ingmar
 CS Dep. Pharmacol., Univ. Lund, Lund, Swed.
 SO Diabetes Res. (1985), 2(4), 207-11
 CODEN: DIREEM
 DT Journal
 LA English
 CC 2-6 (Mammalian Hormones)
 Section cross-reference(s): 1, 14
 AB The pattern of islet lysosomal enzyme activities and the plasma levels of insulin [9004-10-8] and glucose were studied in adult obese

hyperglycemic mice (aged 6-8 mo) after in vivo administration of the lysosomotropic drug suramin [145-63-1]. Suramin (5.2 μ .mol/mouse) gradually decreased plasma insulin levels by .apprx.85% at 20 h postinjection. At the same time point the suramin-induced inhibition of insulin secretion was reflected by a notable (250%) increase in islet insulin content. A neg. correlation was obsd. between plasma insulin levels and islet insulin storage. Plasma glucose levels were not affected by the drug. The activity of acid amyloglucosidase [9032-08-0] in the islets, which is excessively high in the obese mouse, was reduced by .apprx.70% at 20 h after suramin. There was a good correlation between islet amyloglucosidase activity and the plasma insulin concn. in controls and suramin-treated mice. When glycogen was replaced by maltose or 4-methylumbelliferyl-.alpha.-D-glucoside as substrate for the acid .alpha.-1,4-glucoside splitting activity, the inhibitor effect of suramin was less pronounced (.apprx.50%). The ratio of glycogen-splitting to maltose-splitting activity in islet tissue was reduced by suramin from 1.25 (control) to 0.69. The neutral, nonlysosomal .alpha.-1,4-glucoside splitting activity was not affected by the drug. Apart from acid phosphatase activity, which was slightly inhibited, other islet lysosomal enzyme activities were not influenced by suramin administration. Apparently, islet lysosomal enzyme activities can be modulated independently by certain lysosomotropic drugs. Moreover, certain islet lysosomes and(or) lysosomal enzymes, notably acid amyloglucosidase, may be involved in certain insulin-releasing processes and hence may be implicated in the mechanisms of insulin hypersecretion in the obese ob/ob mouse.

ST pancreas islet lysosome insulin obesity; suramin lysosomal enzyme pancreas islet; obesity insulin lysosome pancreas islet

IT Lysosome
(enzymes of, of pancreas islet in obesity, insulin secretion in relation to)

IT Obesity
(insulin secretion in, lysosomal enzymes of pancreas islet in relation to)

IT Pancreatic islet of Langerhans
(lysosomal enzymes of, in hyperglycemia and obesity)

IT Enzymes
RL: BIOL (Biological study)
(of lysosomes, of pancreas islet in obesity, insulin secretion in relation to)

IT Blood sugar
(suramin effect on, in obesity, pancreas islet lysosomal enzymes in relation to)

IT 145-63-1
RL: BIOL (Biological study)
(lysosomal enzymes of pancreas islet response to, insulin secretion in relation to)

IT 9032-08-0
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(of pancreas islet lysosome, suramin effect of, insulin secretion in relation to)


IT 9004-10-8, biological studies
RL: BIOL (Biological study)
(secretion of, in hyperglycemia and obesity, lysosomal enzymes of pancreas islet in relation to)

IT 145-63-1
RL: BIOL (Biological study)
(lysosomal enzymes of pancreas islet response to, insulin secretion in relation to)


RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino)]bis- (9CI)

(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 9004-10-8, biological studies
 RL: BIOL (Biological study)
 (secretion of, in hyperglycemia and obesity, lysosomal enzymes of
 pancreas islet in relation to)
 RN 9004-10-8 HCAPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> d his

(FILE 'HOME' ENTERED AT 15:38:20 ON 23 MAY 2002)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 15:38:31 ON 23 MAY 2002
 E HELMERHORST E/AU

L1 17 S E3,E4,E5
 E PLEWRIGHT B/AU
 L2 1 S E4
 L3 17 S L1,L2

E CURTIN/PA,CS
L4 3783 S E3-E49
L5 5 S L3 AND L4
L6 13 S L3 AND ?INSULIN?
L7 1 S L6 AND (NONPEPTID? OR NON PEPTID?)
L8 1 S L7 AND L5,L6
SEL RN

FILE 'REGISTRY' ENTERED AT 15:41:55 ON 23 MAY 2002

L9 14 S E1-E14
L10 13 S L9 NOT INSULIN
L11 4 S L9 AND F/ELS
L12 1 S L11 AND 5/NR
L13 12 S L10 NOT L12
L14 8 S L13 AND OC5-C6/ES
L15 6 S L14 AND (C25H26O7 OR C28H36O7 OR C27H32N2O6 OR C26H34O7 OR C2
L16 6 S L13 NOT L15
L17 12 S L10 NOT L12

FILE 'HCAPLUS' ENTERED AT 15:59:24 ON 23 MAY 2002

L18 16 S L3 NOT L8
SEL RN

FILE 'REGISTRY' ENTERED AT 15:59:39 ON 23 MAY 2002

L19 13 S E15-E27
L20 12 S L19 NOT L9
L21 55552 S 46.150.18/RID AND OC5-C6/ES AND 3/NR
L22 807 S L21 AND 26/C
L23 131 S L22 AND 5/O
L24 59 S L23 AND METHOXY
L25 46 S L24 NOT N/ELS
L26 4 S L22 AND C26H34O5
L27 STR
L28 0 S L27 CSS
L29 0 S L27 SAM
L30 437 S C26H34O5/MF
L31 6 S L30 AND 46.150.18/RID AND OC5-C6/ES
L32 STR L27
L33 1 S L32
L34 39 S L32 FUL
SAV L34 HOPE400/A
L35 15 S L34 AND 3/NR
L36 8 S L35 NOT N/ELS
SEL RN L20
SEL RN L17
L37 763 S E40-E51/CRN
L38 63 S L37 NOT (COMPD OR MXS/CI)
L39 51 S L38 NOT WITH
L40 19 S L39 AND 4/NR
L41 18 S L40 NOT UNSPECIFIED
SEL RN L12
L42 1 S E52/CRN
L43 2 S L12,L42
L44 30 S L17,L41

FILE 'REGISTRY' ENTERED AT 16:19:44 ON 23 MAY 2002

FILE 'HCAOLD' ENTERED AT 16:22:29 ON 23 MAY 2002

L45 0 S L43

FILE 'HCAPLUS' ENTERED AT 16:22:38 ON 23 MAY 2002

L46 21 S L43
L47 140567 S INSULIN

L48 334734 S GLUCOSE
S INSULIN/CN OR GLUCOSE/CN

L49 FILE 'REGISTRY' ENTERED AT 16:23:20 ON 23 MAY 2002
2 S GLUCOSE/CN

L50 FILE 'HCAPLUS' ENTERED AT 16:23:20 ON 23 MAY 2002
121055 S L49

L51 FILE 'REGISTRY' ENTERED AT 16:23:21 ON 23 MAY 2002
1 S INSULIN/CN

L52 FILE 'HCAPLUS' ENTERED AT 16:23:21 ON 23 MAY 2002
71961 S L51

L53 172109 S L52 OR L50

L54 21 S L46 OR LY292728 OR LY() (292728 OR 292 728)

L55 16 S L54 AND (PD<=19990922 OR PRD<=19990922 OR AD<=19990922)

L56 1 S L54 AND L3,L4

L57 1 S L54 AND L47,L48,L53

L58 1 S L54 AND (?INSULIN? OR GLUCOSE OR BLOOD(L)SUGAR OR ?DIABET? OR

L59 0 S L54 AND (?OBESIT? OR ?OBESE?)

L60 1 S L56-L58
E INSULIN/CT
E E24+ALL

L61 9442 S E11,E10

L62 1 S L54 AND L61

L63 1 S L60,L62

L64 1314 S L44

L65 61 S L64 AND L47,L48,L53,L61

L66 9442 S L61 AND (?INSULIN? OR GLUCOSE OR BLOOD(L)SUGAR OR ?DIABET? OR

L67 458 S L61 AND (?OBESIT? OR ?OBESE?)

L68 8 S L65 AND L66,L67

L69 6995 S L65-L67 NOT INSULIN LIKE GROWTH FACTOR

L70 34 S L69 AND L65

L71 33 S L70 NOT L68

L72 1 S L71 AND ?DIABET?

L73 2 S L63,L72

L74 9 S L51 AND L64

L75 8 S L74 NOT APOPTOSIS/TI

L76 9 S L73,L75
SEL HIT RN

L77 FILE 'REGISTRY' ENTERED AT 16:35:44 ON 23 MAY 2002
14 S E1-E14

L78 1 S L77 NOT L43,L44

L79 FILE 'HCAPLUS' ENTERED AT 16:36:35 ON 23 MAY 2002

L80 FILE 'BIOSIS' ENTERED AT 16:37:02 ON 23 MAY 2002
1 S L54

L81 1962 S L44

L82 10 S L80 AND L51

L83 2 S L80 AND (?DIABET? OR ?HYPOGLYC? OR ?HYPO GLYC?)

L84 12 S L80 AND 17008/CC

L85 16 S L81-L83 AND PY<=1999
E HELMERHORST E/AU

L86 16 S E3,E4,E5
E PLEWRIGHT B/AU

L87 0 S L85 AND L79,L80
9 S L84 NOT 240?/CC

FILE 'EMBASE' ENTERED AT 16:41:17 ON 23 MAY 2002
E HELMERHORST E/AU

L88 22 S E3,E4
 E PLEWRIGHT B/AU
 L89 3 S L54
 L90 3270 S L44
 L91 0 S L89,L90 AND L88
 L92 20 S L89,L90 AND L51
 L93 2 S L92 AND PY=1999

=> d his

(FILE 'HOME' ENTERED AT 15:38:20 ON 23 MAY 2002)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 15:38:31 ON 23 MAY 2002

E HELMERHORST E/AU
 L1 17 S E3,E4,E5
 E PLEWRIGHT B/AU
 L2 1 S E4
 L3 17 S L1,L2
 E CURTIN/PA,CS
 L4 3783 S E3-E49
 L5 5 S L3 AND L4
 L6 13 S L3 AND ?INSULIN?
 L7 1 S L6 AND (NONPEPTID? OR NON PEPTID?)
 L8 1 S L7 AND L5,L6
 SEL RN

FILE 'REGISTRY' ENTERED AT 15:41:55 ON 23 MAY 2002

L9 14 S E1-E14
 L10 13 S L9 NOT INSULIN
 L11 4 S L9 AND F/ELS
 L12 1 S L11 AND 5/NR
 L13 12 S L10 NOT L12
 L14 8 S L13 AND OC5-C6/ES
 L15 6 S L14 AND (C25H26O7 OR C28H36O7 OR C27H32N2O6 OR C26H34O7 OR C2
 L16 6 S L13 NOT L15
 L17 12 S L10 NOT L12

FILE 'HCAPLUS' ENTERED AT 15:59:24 ON 23 MAY 2002

L18 16 S L3 NOT L8
 SEL RN

FILE 'REGISTRY' ENTERED AT 15:59:39 ON 23 MAY 2002

L19 13 S E15-E27
 L20 12 S L19 NOT L9
 L21 55552 S 46.150.18/RID AND OC5-C6/ES AND 3/NR
 L22 807 S L21 AND 26/C
 L23 131 S L22 AND 5/O
 L24 59 S L23 AND METHOXY
 L25 46 S L24 NOT N/ELS
 L26 4 S L22 AND C26H34O5
 L27 STR
 L28 0 S L27 CSS
 L29 0 S L27 SAM
 L30 437 S C26H34O5/MF
 L31 6 S L30 AND 46.150.18/RID AND OC5-C6/ES
 L32 STR L27
 L33 1 S L32
 L34 39 S L32 FUL
 SAV L34 HOPE400/A
 L35 15 S L34 AND 3/NR
 L36 8 S L35 NOT N/ELS
 SEL RN L20

SEL RN L17
L37 763 S E40-E51/CRN
L38 63 S L37 NOT (COMPD OR MXS/CI)
L39 51 S L38 NOT WITH
L40 19 S L39 AND 4/NR
L41 18 S L40 NOT UNSPECIFIED
SEL RN L12
L42 1 S E52/CRN
L43 2 S L12,L42
L44 30 S L17,L41

FILE 'REGISTRY' ENTERED AT 16:19:44 ON 23 MAY 2002

L45 FILE 'HCAOLD' ENTERED AT 16:22:29 ON 23 MAY 2002
0 S L43

L46 FILE 'HCAPLUS' ENTERED AT 16:22:38 ON 23 MAY 2002
21 S L43
L47 140567 S INSULIN
L48 334734 S GLUCOSE
S INSULIN/CN OR GLUCOSE/CN

L49 FILE 'REGISTRY' ENTERED AT 16:23:20 ON 23 MAY 2002
2 S GLUCOSE/CN

L50 FILE 'HCAPLUS' ENTERED AT 16:23:20 ON 23 MAY 2002
121055 S L49

L51 FILE 'REGISTRY' ENTERED AT 16:23:21 ON 23 MAY 2002
1 S INSULIN/CN

L52 FILE 'HCAPLUS' ENTERED AT 16:23:21 ON 23 MAY 2002
71961 S L51
L53 172109 S L52 OR L50
L54 21 S L46 OR LY292728 OR LY() (292728 OR 292 728)
L55 16 S L54 AND (PD<=19990922 OR PRD<=19990922 OR AD<=19990922)
L56 1 S L54 AND L3,L4
L57 1 S L54 AND L47,L48,L53
L58 1 S L54 AND (?INSULIN? OR GLUCOSE OR BLOOD(L) SUGAR OR ?DIABET? OR
L59 0 S L54 AND (?OBESIT? OR ?OBESE?)
L60 1 S L56-L58
E INSULIN/CT
E E24+ALL
L61 9442 S E11,E10
L62 1 S L54 AND L61
L63 1 S L60,L62
L64 1314 S L44
L65 61 S L64 AND L47,L48,L53,L61
L66 9442 S L61 AND (?INSULIN? OR GLUCOSE OR BLOOD(L) SUGAR OR ?DIABET? OR
L67 458 S L61 AND (?OBESIT? OR ?OBESE?)
L68 8 S L65 AND L66,L67
L69 6995 S L65-L67 NOT INSULIN LIKE GROWTH FACTOR
L70 34 S L69 AND L65
L71 33 S L70 NOT L68
L72 1 S L71 AND ?DIABET?
L73 2 S L63,L72
L74 9 S L51 AND L64
L75 8 S L74 NOT APOPTOSIS/TI
L76 9 S L73,L75
SEL HIT RN

L77 FILE 'REGISTRY' ENTERED AT 16:35:44 ON 23 MAY 2002
14 S E1-E14

L78 1 S L77 NOT L43,L44

FILE 'HCAPLUS' ENTERED AT 16:36:35 ON 23 MAY 2002

FILE 'BIOSIS' ENTERED AT 16:37:02 ON 23 MAY 2002

L79 1 S L54
 L80 1962 S L44
 L81 10 S L80 AND L51
 L82 2 S L80 AND (?DIABET? OR ?HYPOGLYC? OR ?HYPO GLYC?)
 L83 12 S L80 AND 17008/CC
 L84 16 S L81-L83 AND PY<=1999
 E HELMERHORST E/AU
 L85 16 S E3,E4,E5
 E PLEWRIGHT B/AU
 L86 0 S L85 AND L79,L80
 L87 9 S L84 NOT 240?/CC

FILE 'EMBASE' ENTERED AT 16:41:17 ON 23 MAY 2002

E HELMERHORST E/AU
 L88 22 S E3,E4
 E PLEWRIGHT B/AU
 L89 3 S L54
 L90 3270 S L44
 L91 0 S L89,L90 AND L88
 L92 20 S L89,L90 AND L51
 L93 2 S L92 AND PY=1999
 SET COST ON